



**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Consolidated Financial Statements

June 30, 2014 and 2013

and

Audit of Federal Awards Performed  
in Accordance with U.S. Office of  
Management and Budget Circular A-133

June 30, 2014

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

**Table of Contents**

	<b>Page(s)</b>
Independent Auditors' Report	1 – 2
Consolidated Balance Sheets	3
Consolidated Statements of Activity	4 – 5
Consolidated Statements of Cash Flows	6
Statements of Functional Expenses	7
Notes to Consolidated Financial Statements	8 – 30
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	31 – 32
Independent Auditors' Report on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with OMB Circular A-133	33 – 35
Schedule of Expenditures of Federal Awards	36 – 43
Notes to Schedule of Expenditures of Federal Awards	44 – 86
Schedule of Findings and Questioned Costs	87



**KPMG LLP**  
Suite 2900  
1918 Eighth Avenue  
Seattle, WA 98101

## **Independent Auditors' Report**

The Board of Trustees  
Fred Hutchinson Cancer Research Center:

### **Report on the Financial Statements**

We have audited the accompanying consolidated financial statements of Fred Hutchinson Cancer Research Center (the Center), which comprise the consolidated balance sheets as of June 30, 2014 and 2013, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### ***Management's Responsibility for the Financial Statements***

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### ***Auditors' Responsibility***

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

***Opinion***

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Center as of June 30, 2014 and 2013, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

**Other Reporting Required by *Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated October 31, 2014 on our consideration of the Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control over financial reporting and compliance.

**KPMG LLP**

October 31, 2014

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Consolidated Statements of Financial Position

June 30, 2014 and 2013

(In thousands)

<b>Assets</b>	<b>2014</b>	<b>2013</b>
	<hr/>	<hr/>
Assets:		
Cash and cash equivalents	\$ 4,016	15,261
Limited use investments	20,907	8,168
Grants and contracts receivable, net	21,594	19,787
Notes and pledges receivable, net	4,794	3,484
Other receivables, net	12,183	19,916
Investments	163,595	134,806
Trustee-held funds	10,929	13,035
Land, buildings, and equipment, net of accumulated depreciation of \$309,064 and \$347,399, respectively	366,904	365,875
Beneficial interest in perpetual trusts	28,644	26,436
Beneficial interest in assets of SCCA	96,584	84,838
Other assets	8,542	9,171
	<hr/>	<hr/>
Total assets	\$ 738,692	700,777
	<hr/>	<hr/>
<b>Liabilities and Net Assets</b>		
Liabilities:		
Accounts payable and accrued liabilities	\$ 12,480	14,105
Accrued payroll and related costs	16,352	22,615
Deferred revenue	40,774	35,453
Long-term debt	358,542	363,516
Deferred credit on cash flow hedges	28,786	30,235
	<hr/>	<hr/>
Total liabilities	456,934	465,924
	<hr/>	<hr/>
Net assets:		
Unrestricted	173,015	146,425
Temporarily restricted	50,607	32,926
Permanently restricted	58,136	55,502
	<hr/>	<hr/>
Total net assets	281,758	234,853
	<hr/>	<hr/>
Total liabilities and net assets	\$ 738,692	700,777
	<hr/>	<hr/>

See accompanying notes to consolidated financial statements.

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Consolidated Statement of Activities

Year ended June 30, 2014

(In thousands)

	<b>2014</b>			
	<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Revenues and other support:				
Research grants and contracts	\$ 314,083	—	—	314,083
Contributions, net of cost of special events of \$1,692	16,208	21,384	388	37,980
Investment income and realized gains and losses	29,452	1,987	—	31,439
Royalty income	7,284	—	—	7,284
Clinical service fee revenue	15,180	—	—	15,180
Other income	30,584	—	—	30,584
Net assets released from restrictions	8,652	(8,652)	—	—
Total revenues	<u>421,443</u>	<u>14,719</u>	<u>388</u>	<u>436,550</u>
Expenses:				
Program services research	320,511	—	—	320,511
Management and general	85,538	—	—	85,538
Fund-raising	8,257	—	—	8,257
Total expenses	<u>414,306</u>	<u>—</u>	<u>—</u>	<u>414,306</u>
Change in net assets from operations	<u>7,137</u>	<u>14,719</u>	<u>388</u>	<u>22,244</u>
Other changes in net assets:				
Change in net unrealized fair value of investments	18,337	2,890	—	21,227
Change in net foreign currency translation	(162)	—	—	(162)
Change in value of split-interest agreements	(171)	72	2,246	2,147
Change in net unrealized fair value of swap instruments	1,449	—	—	1,449
Total other changes in net assets	<u>19,453</u>	<u>2,962</u>	<u>2,246</u>	<u>24,661</u>
Total increase in net assets	<u>26,590</u>	<u>17,681</u>	<u>2,634</u>	<u>46,905</u>
Net assets balance at beginning of year	<u>146,425</u>	<u>32,926</u>	<u>55,502</u>	<u>234,853</u>
Net assets balance at end of year	\$ <u><u>173,015</u></u>	<u><u>50,607</u></u>	<u><u>58,136</u></u>	<u><u>281,758</u></u>

See accompanying notes to consolidated financial statements.

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Consolidated Statements of Activities

Year ended June 30, 2013

(In thousands)

	<u>Unrestricted</u>	<u>Temporarily restricted</u>	<u>Permanently restricted</u>	<u>Total</u>
Revenues and other support:				
Research grants and contracts	\$ 327,949	—	—	327,949
Contributions, net of cost of special events of \$961	12,530	5,294	1,356	19,180
Investment income and realized gains and losses	9,487	1,175	—	10,662
Royalty income	5,466	—	—	5,466
Clinical service fee revenue	16,720	—	—	16,720
Other income	26,727	—	—	26,727
Net assets released from restrictions	8,502	(8,502)	—	—
Total revenues	<u>407,381</u>	<u>(2,033)</u>	<u>1,356</u>	<u>406,704</u>
Expenses:				
Program services research	331,489	—	—	331,489
Management and general	86,778	—	—	86,778
Fund-raising	9,251	—	—	9,251
Total expenses	<u>427,518</u>	<u>—</u>	<u>—</u>	<u>427,518</u>
Change in net assets from operations	<u>(20,137)</u>	<u>(2,033)</u>	<u>1,356</u>	<u>(20,814)</u>
Other changes in net assets:				
Change in net unrealized fair value in investments	10,569	(3,096)	31	7,504
Change in net foreign currency translation	(210)	—	—	(210)
Change in value of split-interest agreements	(306)	—	870	564
Change in net unrealized fair value of swap instruments	14,474	—	—	14,474
Total other changes in net assets	<u>24,527</u>	<u>(3,096)</u>	<u>901</u>	<u>22,332</u>
Total increase (decrease) in net assets	4,390	(5,129)	2,257	1,518
Net assets balance at beginning of year	<u>142,035</u>	<u>38,055</u>	<u>53,245</u>	<u>233,335</u>
Net assets balance at end of year	\$ <u><u>146,425</u></u>	\$ <u><u>32,926</u></u>	\$ <u><u>55,502</u></u>	\$ <u><u>234,853</u></u>

See accompanying notes to consolidated financial statements.

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Consolidated Statements of Cash Flows

Years ended June 30, 2014 and 2013

(In thousands)

	<u>2014</u>	<u>2013</u>
Cash flows from operating activities:		
Change in net assets	\$ 46,905	1,518
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	24,710	27,592
Decrease in noncash deferred revenue	(715)	(1,145)
Equity in earnings of SCCA	(11,746)	(2,725)
Change in net unrealized gains in fair value of investments	(21,227)	(7,504)
Change in value of split-interest agreements	(2,208)	(564)
Change in fair value of swap instruments	(1,449)	(14,474)
Net realized gains on investments	(17,688)	(5,066)
Noncash contributions	(13,396)	(2,863)
Permanently restricted contributions	(388)	(1,356)
Changes in assets and liabilities:		
Grants and contracts receivable	(1,807)	6,564
Notes and pledges receivable	(1,310)	1,785
Other receivables	7,856	(2,541)
Prepaid expenses and deposits	437	264
Accounts payable and accrued liabilities	(1,627)	(9,497)
Accrued payroll and related costs	(6,263)	5,328
Deferred grant and contract revenue	5,553	4,781
Net cash provided by operating activities	<u>5,637</u>	<u>97</u>
Cash flows from investing activities:		
Additions to land, buildings, equipment, and rental property	(25,619)	(37,824)
Purchase of investments	(42,707)	(47,999)
Sale of investments	40,096	68,756
Change in trustee-held funds	2,106	16,588
Net cash used in investing activities	<u>(26,124)</u>	<u>(479)</u>
Cash flows from financing activities:		
Proceeds from new debt	—	142,485
Additions to deferred financing costs	—	(234)
Repayment of debt	(4,931)	(146,595)
Contributions restricted for long-term investment	13,784	1,356
Net cash provided by (used in) financing activities	<u>8,853</u>	<u>(2,988)</u>
Change in foreign currency translation	<u>389</u>	<u>356</u>
Net decrease in cash and cash equivalents	(11,245)	(3,014)
Cash and cash equivalents at beginning of year	<u>15,261</u>	<u>18,275</u>
Cash and cash equivalents at end of year	\$ <u><u>4,016</u></u>	\$ <u><u>15,261</u></u>
Supplemental disclosure of cash flow information:		
Interest paid	\$ 18,527	17,152
Capital expenditures in accounts payable	365	395

See accompanying notes to consolidated financial statements.



**FRED HUTCHINSON CANCER RESEARCH CENTER**

Consolidated Statements of Functional Expenses

Years ended June 30, 2014 and 2013

(In thousands)

	<b>Program services research</b>	<b>Management and general</b>	<b>Fundraising</b>	<b>Total</b>
2014:				
Salaries and wages	\$ 139,700	37,916	4,647	182,263
Employee benefits	36,983	8,041	1,169	46,193
Subawards	62,194	—	—	62,194
Purchased services	10,265	13,658	962	24,885
Supplies	21,147	2,390	99	23,636
Other	10,523	6,553	1,311	18,387
Rent, utilities, and maintenance	3,209	10,246	69	13,524
Interest and amortization	16,798	1,867	—	18,665
Depreciation	19,692	4,867	—	24,559
Total June 30, 2014	\$ <u>320,511</u>	<u>85,538</u>	<u>8,257</u>	<u>414,306</u>
2013:				
Salaries and wages	\$ 143,931	35,134	5,082	184,147
Employee benefits	40,363	9,291	1,366	51,020
Subawards	64,385	—	—	64,385
Purchased services	9,243	16,674	986	26,903
Supplies	22,710	2,580	60	25,350
Other	10,340	4,846	1,716	16,902
Rent, utilities, and maintenance	2,692	11,023	41	13,756
Interest and amortization	16,135	1,789	—	17,924
Depreciation	21,690	5,441	—	27,131
Total June 30, 2013	\$ <u>331,489</u>	<u>86,778</u>	<u>9,251</u>	<u>427,518</u>

See accompanying notes to consolidated financial statements.

# FRED HUTCHINSON CANCER RESEARCH CENTER

## Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

### (1) Organization

Fred Hutchinson Cancer Research Center (the Center), a Washington not-for-profit corporation, is organized and operated exclusively for charitable, scientific, and educational purposes, within the meaning of Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, including without limitation (i) eliminating cancer as a cause of human suffering and death; (ii) conducting investigations into the nature and causes of cancer and related medical and public health problems; (iii) investigating methods of prevention and treatment of cancer and related diseases; (iv) conducting education in all phases of cancer research; (v) performing research in all aspects of biomedical science that have a relationship to cancer; (vi) disseminating knowledge acquired pursuant to the foregoing activities; and (vii) maintaining facilities for cancer and related biomedical research. The Center is designated by the National Cancer Institute as a comprehensive cancer research center.

#### *Controlled Affiliates of the Center*

Hutchinson Centre Research Institute in Uganda Limited (HCRIU), formerly known as Uganda Program on Cancer and Infectious Disease, is a Uganda not-for-profit corporation. It is organized and operated for the purpose of researching, detecting, treating and preventing infection-related cancers in Uganda and throughout the world. The Center is the sole member of HCRIU. The income and property of HCRIU is restricted to be used in meeting its organizational objectives. The net assets of HCRIU of \$(1,159) and \$(966) as of June 30, 2014 and 2013, respectively, are not considered pledged assets under debt covenants.

Hutchinson Centre Research Institute of South Africa (HCRISA) is a South Africa not-for-profit corporation. It is organized and operated for the purpose of promoting and conducting clinical, laboratory and other research aimed at the prevention, early detection, diagnosis, and treatment of HIV/AIDS, Tuberculosis other infectious diseases and cancer in South Africa and throughout the world. The Center is the sole member of HCRISA. The income and property of HCRISA is restricted to be used in meeting its organizational objectives. The net assets of HCRISA of \$(162) and \$(170) as of June 30, 2014 and 2013, respectively, are not considered pledged assets under debt covenants.

Seattle Vaccine Research Fund (SVRF), a Washington State not-for-profit corporation, is exempt from federal taxes under Section 501(c)(3). It is operated for the purpose of providing anti retrovirals to eligible participants of HIV Trials Network participants. The net assets of SVRF of \$441 and \$439 as of June 30, 2014 and 2013, respectively, are not considered pledged assets under debt covenants.

### (2) Summary of Significant Accounting Policies

#### (a) *Basis of Presentation*

The consolidated financial statements include the accounts of the Center and its controlled affiliates, collectively referred to as the Center. All significant intracompany balances and transactions between the Center and its controlled affiliates have been eliminated in consolidation.

#### (b) *Use of Estimates*

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**(c) Cash and Cash Equivalents**

Included in cash and cash equivalents are cash equivalents of approximately \$314 and \$3,314 as of June 30, 2014 and 2013, respectively, which are invested in money market funds and highly liquid debt instruments with original maturities of three months or less.

The Center maintains cash and cash equivalents on deposit at financial institutions, which at times exceed the limits insured by the Federal Deposit Insurance Corporation. This exposes the Center to potential risk of loss in the event that the financial institution becomes insolvent.

**(d) Limited use Investments**

Limited use investments includes designated unrestricted financial assets set aside by the board of trustees for future capital and program purposes, over which the board of trustees retains control and may at its discretion subsequently use for other purposes.

**(e) Investments**

Investments, including board-designated investments and other restricted investments, carried at fair value include cash and cash equivalents, equity securities, debt securities, and alternative investments.

**(f) Trustee Held Funds**

The components of trustee-held funds and the purposes for which they are being held as of June 30 are as follows:

	<u>2014</u>	<u>2013</u>
Trustee-held funds:		
Cash equivalents	\$ —	2,437
U.S. government and agency obligations	10,929	8,919
Corporate bonds	—	1,679
	<u>\$ 10,929</u>	<u>13,035</u>
Purpose for which funds are held:		
Series 2012B Bond Project Fund	\$ —	2,433
Debt service reserve funds	10,929	10,602
	<u>\$ 10,929</u>	<u>13,035</u>

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

**(g) Land, Buildings, and Equipment**

Land, buildings, and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized as a component of the cost of acquiring those assets. Improvements and replacements of land, buildings, and equipment are capitalized; maintenance and repairs costs are expensed.

In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360, *Property, Plant, and Equipment*, long-lived assets, such as property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable.

As described in note 3, the Center receives reimbursement for its property, plant, and equipment through indirect cost reimbursement primarily from the federal government in connection with federal grants.

**(h) Beneficial Interest in Assets of SCCA**

The Center accounts for its 33% ownership interest in Seattle Cancer Care Alliance (SCCA) using the equity method of accounting, as further discussed in note 14.

**(i) Deferred Financing Costs**

Financing costs incurred in connection with long-term obligations are deferred and amortized over the term of the credit enhancement facility for variable rate debt or the term of the debt using the effective interest method for fixed rate debt.

**(j) Deferred Grant and Contract Revenue and Research Grants and Contracts Receivable**

The Center includes certain construction grants from the federal government as deferred revenue, which are recognized as revenue at the same rate as depreciation expense. Deferred grant and contract revenue represent grant and contract funds received for services to be performed by the Center, which have not yet been expended under terms of the grant and contract agreements and which do not meet the criteria for reporting as contributions. The Center recognizes these amounts as revenue as such funds are expended.

The balance in grants and contracts receivable, as reflected on the accompanying balance sheets, represents expenditures made in accordance with the terms of provisions of the grants and contracts not yet reimbursed by cash.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

**(k) Donor-Restricted Gifts**

Unconditional promises to give cash and other assets to the Center are reported at fair value at the date the promise is received. Conditional promises to give and intentions to give are reported at fair value at the date the gift is received or the conditions are met. The gifts are reported as either temporarily or permanently restricted support if they are received with donor stipulations that limit the use of the donated assets or contain a time restriction. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and reported in the statements of activity as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying financial statements.

**(l) Foreign Currency Translation and Transaction Gains and Losses**

The consolidated financial statements include foreign currency amounts attributable to foreign operations for HCRISA. The foreign currency amounts have been translated into U.S. dollars using year-end exchange rates for assets and liabilities, historical rates for net assets and average annual rates for revenues and expenditures. Unrealized gains or losses arising from fluctuations in the year-end exchange rates are recorded as net asset adjustments from foreign currency translation, and gains or losses resulting from actual foreign exchange transactions are recorded in revenues and expenses in the consolidated statements of activities. The cumulative foreign currency translation losses amount to \$139 and \$210 at June 30, 2014 and 2013, respectively.

In accordance with the ASC Topic 230, *Statement of Cash Flows*, cash flows from the HCRISA's operations are calculated based on its local reporting currency and translated to U.S. dollars.

HCRIU's general ledger is maintained in U.S. dollars, and their financial statements are measured using the currency of the primary economic environment in which the entity operates, which is U.S. dollars. Unrealized gains or losses arising from fluctuations in the year-end exchange rates, and gains or losses resulting from actual foreign exchange transactions are recorded in revenues and expense. The cumulative foreign currency translation losses amount to \$23 at June 30, 2014.

**(m) Temporarily and Permanently Restricted Net Assets**

Temporarily restricted net assets are those that have uses that have been limited by donors to a specific time period or purpose. The Center's temporarily restricted net assets are restricted to scientific research expenses and equipment, the acquisition of long-term assets related to Center expansion, and designated noncapitalizable activities related to Center expansion.

Permanently restricted net assets have been restricted by donors to be maintained by the Center in perpetuity. The Center's permanently restricted net assets consist of various endowment funds and the Center's interest in perpetual trusts. Income earned on endowment funds is used for operations in accordance with the terms of each endowment fund.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

**(n) *Statements of Activities***

The statements of activities describe the results of various financial events that are included in presenting the change in the Center's net assets. Contributions received by the Center may be either unrestricted, temporarily restricted, or permanently restricted. Investment income and realized gains and losses may be temporarily restricted based on donor intent or unrestricted. Research grant and contract revenue generated by the Center and related expenses incurred are unrestricted. Changes in asset values resulting from "mark-to-market" adjustments to record unrealized gains and losses are shown as Other Changes in Net Assets. A total increase or decrease in net assets for each net asset grouping is shown to roll forward the beginning of the year balance to the end of the year balance.

**(o) *Federal Income Taxes***

The Center has obtained a determination letter from the Internal Revenue Service that it is exempt from federal income taxes under Section 501(c)(3), except for unrelated business income.

**(p) *Fair Value Option***

FASB ASC Section 825, *Financial Instruments*, gives an entity the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument-by-instrument basis, with changes in fair value reported in change in net assets from operations. The Center has elected not to adopt the provisions of this standard for the years ended June 30, 2014 and 2013.

**(3) *Due from Government Agencies***

The Center incurs facilities and administrative (F&A) costs to support its research activities. Research programs are charged for these costs through an F&A cost rate, which is applied to modified total direct research costs. Both direct and F&A costs are recovered by the Center from research programs supported by federal and other grant revenue.

The fixed federal F&A rate for grant and contract supported programs is determined by prospective negotiation with the Department of Health and Human Services (DHHS) based on an estimate of the costs that will be incurred during the period to which the rate applies. Any difference between the costs recovered through the fixed F&A cost rate and actual F&A costs incurred represents an estimated F&A settlement with the federal government, which will be included in future rates. No estimated settlement was recorded as of June 30, 2014 or 2013.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

#### (4) Investments

The following table summarizes the Center's Level 3 investments (excluding trustee-held funds and equity method investments) by major category, as well as related strategy, liquidity, and funding commitment as of June 30:

	<u>June 30, 2014</u>	<u>June 30, 2013</u>	<u>Redemption or liquidation</u>	<u>Days notice</u>	<u>Unfunded commitment</u>
Directional hedge funds	\$ 24,660	20,433	Qtrly – Every 2 yrs	30 – 184	N/A
Limited partnerships:					
Venture capital	989	949	N/A (1)	N/A	N/A
Private equity	7,837	8,512	N/A (1)	N/A	409
Private real assets	3,617	3,895	N/A (1)	N/A	(3)
Private real assets	3,579	3,185	Quarterly	90	N/A
Custodial held securities	71	98	Daily	One	N/A
Other equity securities	15,076	5,646	N/A (1)	N/A	N/A
Other real and personal property	721	721	N/A (2)	N/A	N/A
Total investments	<u>\$ 56,550</u>	<u>43,439</u>			

(1) Not eligible for redemption

(2) Redeemable after 2030

(3) Unfunded Commitment of \$671 and \$694 as of June 30, 2014 and 2013, respectively

At June 30, 2014 and 2013, the Center had \$28,240 and \$14,222, respectively, in investments that are not readily marketable. These are investments for which liquidation is at the discretion of the fund manager. These investments represent 15% and 10% of total investments and 10% and 6% of net assets at June 30, 2014 and 2013, respectively. These investment instruments may contain elements of both credit and market risk. Such risks include, but are not limited to, limited liquidity, absence of regulatory oversight, dependence upon key individuals, emphasis on speculative investments (both derivatives and nonmarketable investments), and nondisclosure of portfolio composition. Because of these risks, the recorded value for these investments may differ from the value that would have been used had a ready market for such investments existed. Such differences could be material.

The Center has funds invested in 30 limited partnerships and companies with ownership interests ranging from 0.32% to 4.61% at June 30, 2014 and 2013. In 2014, three of these partnerships are venture capital funds, four are private equity, eighteen are hedge funds, three are debt funds, and two are real estate funds.

The Center's restricted investments contain endowment funds with donor restrictions for a variety of purposes. The Center's board-designated investments include funds designated by the board of trustees to function as endowments. The board of trustees may also periodically remove designations on funds previously designated. As required by GAAP, net assets associated with endowment funds, including funds designated by the board of trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

Components of investment income for the years ended June 30 are as follows:

	<u>2014</u>	<u>2013</u>
Interest	\$ 1,784	1,975
Dividends	1,221	1,807
Net realized gains	17,688	5,066
Equity in earnings of SCCA investment	<u>11,728</u>	<u>2,648</u>
	32,421	11,496
Less investment management fees	<u>(982)</u>	<u>(834)</u>
	<u>\$ 31,439</u>	<u>10,662</u>

Fair value is defined as the price that the Center would receive upon selling an asset in an orderly transaction to an independent buyer in the principal or most advantageous market of the investment. FASB ASC 820-10-50, *Fair Value Measurement*, established a three-tier hierarchy to maximize the use of observable market data and minimize the use of unobservable inputs, and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based upon market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available. The three-tier hierarchy is summarized below:

- Level 1 – Valuation inputs are quoted prices in active markets for identical investments. At June 30, 2014 and 2013, Level 1 measurements include primarily cash and cash equivalents, domestic and global equities, equity funds, and bond funds.
- Level 2 – Valuation inputs are quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. At June 30, 2014 and 2013, Level 2 measurements included fixed income and debt securities, such as U.S. government obligations, mortgage-backed securities, corporate bonds, municipal obligations, interest rate swaps, and certain hedged equity and real asset funds.
- Level 3 – Valuation inputs are derived from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Center's estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of discounted cash flow models and similar techniques. At June 30, 2014 and 2013, Level 3 securities included hedged equity funds, private equity and venture capital funds, privately held equities, beneficial interests in charitable trusts, and beneficial interests in perpetual trusts.



## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

The fair value of alternative investments is reported based on information provided by the respective alternative investment funds' managers. The alternative investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed to direct interests in the fund's underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of the Center's interest therein, its classification in Level 2 or 3 is based on the Center's ability to redeem its interest at or near the balance sheet date. If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

*(a) Fair Value Calculation Methodology*

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:

**Cash and Cash Equivalents** – The carrying amount (cost) approximates fair value because of the short maturity of those instruments.

**Investments and Trustee-Held Funds** – Investments in equity and debt securities, trustee-held funds, beneficial interest in charitable remainder trusts and perpetual trusts are measured at fair value based on quoted market prices, if available, or estimated using quoted market prices for similar securities. Alternative investments are measured at fair value based on each fund's net asset value as a practical expedient. Other equity securities, which are shares held in a nonpublic entity, are measured at fair value based on management's valuation model. Management's model utilizes data and assumptions that are not observable to market participants.

**Long-Term Debt** – The carrying amount of long-term debt with variable interest rates approximates fair value because interest rates are adjusted either daily or weekly for the variable rate demand bonds. The carrying amount of the fixed rate debt is calculated based upon the net present value of the future cash outflows of the associated fixed rate debt discounted at the interest rates in effect as of June 30, 2014.

**Cash Flow Hedges** – The carrying amounts of the interest rate swaps are at estimated fair values based on the net present value of the associated variable cash flows, adjusted for the Center's and the respective counterparty's nonperformance risk.

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

**(b) Fair Value Hierarchy**

The following tables present assets and liabilities that are measured at fair value on a recurring basis at June 30, 2014 and 2013:

	<b>2014</b>			
	<b>June 30, 2014</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Investments:				
Cash and cash equivalents	\$ 30,887	30,887	—	—
Global equity securities and mutual funds	62,516	42,546	19,970	—
Governments, mortgage and corporate debt funds	15,522	5,637	9,814	71
Global real estate funds	8,614	341	8,273	—
Directional hedge securities	34,539	—	9,879	24,660
Private equity and venture capital funds	8,826	—	—	8,826
Real estate hedge funds	7,196	—	—	7,196
Other equity securities	15,440	364	—	15,076
Other real and personal property	721	—	—	721
Commodity index fund	241	—	241	—
Total investments	\$ <u>184,502</u>	<u>79,775</u>	<u>48,177</u>	<u>56,550</u>

	<b>2014</b>			
	<b>June 30, 2014</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Other receivables:				
Beneficial interest in charitable remainder trusts	\$ 1,952	—	—	1,952
Beneficial interest in perpetual trusts	28,644	—	—	28,644
Trustee-held funds	10,929	—	10,929	—
Liabilities:				
Deferred credit on cash flow hedges	\$ (28,786)	—	(28,786)	—

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

	<b>2013</b>			
	<b>June 30, 2013</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
<b>Investments:</b>				
Cash and cash equivalents	\$ 12,631	12,631	—	—
Global equity securities and mutual funds	51,842	34,230	17,612	—
Governments, mortgage and corporate debt funds	15,494	10,003	5,393	98
Commodity hedging fund	8,027	—	8,027	—
Global real estate funds	300	300	—	—
Directional hedge securities	31,525	—	11,092	20,433
Private equity and venture capital funds	9,461	—	—	9,461
Real estate hedge funds	7,080	—	—	7,080
Other equity securities	5,748	102	—	5,646
Other real and personal property	721	—	—	721
Commodity index fund	145	—	145	—
<b>Total investments</b>	<b>\$ 142,974</b>	<b>57,266</b>	<b>42,269</b>	<b>43,439</b>

	<b>2013</b>			
	<b>June 30, 2013</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
<b>Other receivables:</b>				
Beneficial interest in charitable remainder trusts	\$ 1,849	—	—	1,849
Beneficial interest in perpetual trusts	26,436	—	—	26,436
Trustee-held funds	13,035	2,437	10,598	—
<b>Liabilities:</b>				
Deferred credit on cash flow hedges	(30,235)	—	(30,235)	—

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

The following tables presents the Center’s activities for assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended June 30, 2014 and 2013:

	<u>2014</u>	<u>2013</u>
Beginning balance, July 1	\$ 71,724	77,037
Transfers into (out of) Level 3	(15)	(4,886)
Net realized and unrealized gains	24,645	4,879
Purchases	4,623	384
Sales	(9,581)	(3,357)
Return of capital distribution	<u>(4,250)</u>	<u>(2,333)</u>
Ending balance, June 30	\$ <u>87,146</u>	<u>71,724</u>

**(5) Endowments**

**(a) Return Objectives and Risk Parameters**

The Center has adopted investment and spending policies for its endowment that will provide resources to programs supported by the endowment. The endowment includes donor-restricted funds as well as board-designated investments. Under this policy, as approved by the Center’s board of trustees, the primary objective of the investment of the endowment is to provide a rate of total return, including all gains and losses, realized and unrealized, which exceeds the rate of inflation (as represented by the Consumer Price Index-All Urban Consumers) plus 5% over the long term. The Center defines the long term as five years and more. Consistent returns are to be emphasized over individual year results, although the possibility of loss in a given year cannot be ignored. The endowment should experience risk (volatility and variability of return) no greater than that of the market. The Center defines the market as the portfolio’s asset allocation policy applied to the Russell 3000 Index, the Morgan Stanley Capital Europe, Australia, Far East (EAFE) Index or its equivalent, and the iShares Barclays Aggregate Bond Index.

**(b) Strategies Employed for Achieving Objectives**

The Center relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends) to achieve its long-term rate of return objectives. The Center utilizes an efficient frontier approach to establish the appropriate asset allocation balancing long-term return objectives within prudent risk constraints. The Finance Committee of the Center’s board of trustees reviews the Center’s asset allocation at least once a year.

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

**(c) Spending Policies and How the Investment Objectives Relate to Spending Policies**

The Center's spending policy for endowment funds is to appropriate for distribution each year 5% of the endowment fund's average fair value over the prior three years, provided that the fair value of the endowment fund exceeds the corpus. For a portion of the Center's board-designated investments, the Center does not appropriate for distribution any amount of investment return as all of the return earned is held to grow the fund for future repayment of long-term debt. For the remaining board-designated investments, the Center makes all investment return available for expenditure to support research. In establishing these policies, the Center considered the long-term expected returns on its endowment and board-designated investments.

**(d) Funds with Deficiencies**

Unless otherwise agreed with the donor, the Center's policy has been to maintain the value of the original corpus of each individual donor-restricted endowment fund. From time to time, the fair value of assets in such endowment funds may fall below this level or such other level as may have been agreed to by the donor or required by law. Losses on the investments of a donor-restricted endowment fund reduce temporarily restricted net assets to the extent that donor-imposed restrictions on net appreciation of the fund have not been met before a loss occurs and any remaining loss reduces unrestricted net assets. As of June 30, 2014 and 2013, the aggregate reduction from unrestricted net assets totaled \$0 and \$43, respectively.

The following tables show the net asset composition of the Center's endowment funds by type of fund as of June 30, 2014 and 2013:

		<b>2014</b>			
		<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Donor-restricted endowment funds	\$	—	16,053	28,607	44,660
Board-designated endowment funds		99,553	—	—	99,553
Total	\$	<u>99,553</u>	<u>16,053</u>	<u>28,607</u>	<u>144,213</u>
		<b>2013</b>			
		<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Donor-restricted endowment funds	\$	(43)	2,735	27,286	29,978
Board-designated endowment funds		85,669	8,570	—	94,239
Total	\$	<u>85,626</u>	<u>11,305</u>	<u>27,286</u>	<u>124,217</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

The following tables show the activity that has occurred within the endowment net asset accounts for the years ended June 30, 2014 and 2013:

	<b>2014</b>			<b>Total</b>
	<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	
Endowment net assets, beginning of year	\$ 85,626	11,305	27,286	124,217
Investment return:				
Investment income	541	193	—	734
Net realized gain	6,462	1,781	—	8,243
Net unrealized gain	7,757	2,863	—	10,620
Total investment return	14,760	4,837	—	19,597
Contributions	—	1,062	1,321	2,383
Distributions	(1,018)	—	—	(1,018)
Board transfers in	1,934	—	—	1,934
Board transfers out	(1,749)	—	—	(1,749)
Appropriation of endowment assets for expenditure	—	(1,151)	—	(1,151)
Endowment net assets, end of year	\$ 99,553	16,053	28,607	144,213

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

	<b>2013</b>			<b>Total</b>
	<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	
Endowment net assets, beginning of year	\$ 87,970	4,320	25,623	117,913
Investment return:				
Investment income	1,134	414	—	1,548
Net realized gain	1,994	761	—	2,755
Net unrealized gain	5,801	1,792	—	7,593
Total investment return	8,929	2,967	—	11,896
Contributions	—	5,050	1,663	6,713
Distributions	(7,681)	—	—	(7,681)
Board transfers in	408	—	—	408
Board transfers out	(4,000)	—	—	(4,000)
Appropriation of endowment assets for expenditure	—	(1,032)	—	(1,032)
Endowment net assets, end of year	\$ <u>85,626</u>	<u>11,305</u>	<u>27,286</u>	<u>124,217</u>

**(6) Land, Buildings, and Equipment**

Summaries of land, buildings, and equipment at cost as of June 30 are as follows:

	<b>2014</b>	<b>2013</b>
Land	\$ 52,389	52,389
Buildings and improvements	471,831	463,599
Equipment	132,558	184,612
Construction in progress	19,188	12,674
	<u>675,966</u>	<u>713,274</u>
Less accumulated depreciation	<u>(309,062)</u>	<u>(347,399)</u>
	\$ <u><u>366,904</u></u>	<u><u>365,875</u></u>

Buildings are depreciated on a straight-line basis over 45 years, while improvements and equipment are depreciated over 3 to 30 years, depending on the nature of the asset. Interest expense on borrowed funds during construction is a component of the cost of assets. The amount capitalized represents interest on

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

funds expended for construction. Capitalization of interest ceases when the asset is placed in service. The Center capitalized \$0 and \$949 of interest in 2014 and 2013, respectively.

**(7) Notes and Pledges Receivable**

Components of notes and pledges receivable as of June 30 are as follows:

	<u>2014</u>	<u>2013</u>
Amounts due in:		
Less than one year	\$ 4,543	2,537
One to five years	2,588	3,318
Less:		
Unamortized discount	(31)	(65)
Allowance for uncollectible pledges	<u>(2,306)</u>	<u>(2,306)</u>
Notes and pledges receivable, net	<u>\$ 4,794</u>	<u>3,484</u>

As of June 30, 2014 and 2013, the gross notes and pledges receivable balances include pledges with a donor-restricted purpose of \$4,009 and \$3,002, respectively. The discounts on pledges are computed at the rate commensurate with the risks applicable to the year in which the promise is received. Notes and pledges have been discounted using a rate ranging from 2.5% to 5.0%.

**(8) Long-Term Debt**

Summaries of long-term debt as of June 30 are as follows:

	<u>2014</u>	<u>2013</u>
Series 2007 Revenue Bonds at a fixed interest rate of 4.72% secured by a deed of trust due in amounts ranging from \$145 in 2014 to \$4,359 in 2015	\$ 4,359	4,504
Series 2009A Revenue Bonds at fixed interest rates ranging from 3.50% to 6.00% secured by a deed of trust due in amounts ranging from \$2,895 in 2014 to \$4,930 in 2033	103,975	106,870
Series 2010 Revenue Bonds at a variable interest rate averaging 1.48% and 1.50% for the years ended June 30, 2014 and 2013 secured by a deed of trust due in amounts ranging from \$926 in 2014 to \$2,228 in 2032	27,352	28,278
Series 2011A Revenue Bonds at fixed interest rates ranging from 0.50% to 6.00% secured by a deed of trust due in amounts ranging from \$965 in 2014 to \$4,795 in 2035	81,930	82,895



**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

	<u>2014</u>	<u>2013</u>
Series 2012A Revenue Bonds at a variable interest rate averaging 1.23% and 1.26% for the years ended June 30, 2014 and 2013 secured by a deed of trust due in amounts ranging from \$6,110 in 2035 to \$9,165 in 2041	\$ 57,685	57,685
Series 2012B Revenue Bonds at a variable interest rate averaging 1.25% and 1.29% for the years ended June 30, 2014 and 2013 secured by a deed of trust due in amounts ranging from \$8,355 in 2035 to \$13,578 in 2041	84,800	84,800
	<u>360,101</u>	<u>365,032</u>
Unamortized (discount)	<u>(1,559)</u>	<u>(1,516)</u>
	<u>\$ 358,542</u>	<u>363,516</u>
Fair value disclosure (note 4)	\$ 383,498	387,398

On August 30, 2012, the Center issued through the Washington Health Care Facilities Authority (the Authority) \$57,685 of tax-exempt revenue bonds Series 2012A (2012A Bonds) and an \$84,800 tax-exempt revenue bond Series 2012B (2012B Bond). The 2012A Bonds are variable rate bonds used to refund the 2011B bonds. The 2012A Bonds were issued under a private placement with JP Morgan Chase Bank, N.A. The 2012B Bond is a variable rate bond used to refund the 2011C Bonds. The 2012B Bond was issued under a private placement with Bank of America, N.A. and all interest and principal payments are made directly to the bank.

On June 30, 2011, the Center issued through the Authority \$84,150 of tax-exempt revenue bonds Series 2011A (2011A Bonds), \$57,525 of tax-exempt revenue bonds Series 2011B (2011B Bonds) and \$84,500,000 of tax-exempt revenue bonds Series 2011C (2011C Bonds). The 2011A Bonds are fixed rate bonds issued under the Center's credit rating with interest rates ranging from 0.50% to 6.00% used to refund a portion of the 2001A Bonds and the 2009B Bonds. The 2011B Bonds are variable rate bonds used to refund a portion of the 2001A Bonds and the 2009B Bonds, and fund most of the repayment of a bridge loan used to acquire the 1100 Eastlake Building. The 2011C Bonds are variable rate bonds used to refund a portion of the 2001A Bonds and the 2009B Bonds, fund the remainder of the bridge loan repayment and fund the alterations to be made to the 1100 Eastlake Building.

On November 4, 2010, the Center issued through the Authority a \$30,000 tax-exempt revenue bond Series 2010 (2010 Bond). The 2010 Bond is a variable rate bond used to purchase the Yale Building from National Healthcare Research and Education Finance Corporation (NHREFCO) (note 11). The 2010 Bond was issued under a private placement with JP Morgan Chase Bank, N.A. and all interest and principal payments are made directly to the bank.

On November 24, 2009, the Center issued through the Authority \$114,920 of tax-exempt revenue bonds Series 2009A (2009A Bonds). The 2009A Bonds are fixed rate bonds issued under the Center's credit

# FRED HUTCHINSON CANCER RESEARCH CENTER

## Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

rating with interest rates ranging from 3.50% to 6.00% and were used to refund the 2001B Bonds and 2002 Bonds.

On November 15, 2007, the Center issued through the Authority \$5,200 of tax-exempt revenue bonds Series 2007 (2007 Bonds). The 2007 Bonds are fixed rate bonds used to reimburse the Center for the purchase of property on the Center's campus. The deed of trust only secures this specific property on the Center's campus.

The bond documents for the 2009A Bonds, 2010 Bond, 2011A Bonds, 2012A Bonds and 2012B Bond have covenants that require the Center to provide to the Authority, pursuant to a deed of trust, a mortgage and security interest in substantially all of the real estate and improvements owned by the Center, a security interest in the funds held by the trustees, and in the gross receivables and equipment owned by the Center. The bond documents for the 2011B Bonds and 2011C Bonds require the Center to maintain unrestricted and unencumbered cash, cash equivalents, and marketable debt and equity securities of at least 75 days of cash operating expenses less subaward expenses and net income available for debt service must exceed 150% of the debt service in the same year. The bond documents for the 2012A Bonds and 2012B Bond require the Center to maintain unrestricted and unencumbered cash, cash equivalents, and marketable debt and equity securities of at least 80 days of cash operating expenses less subaward expenses and net income available for debt service must exceed 150% of the debt service in the same year. The bond documents for the 2009A Bonds require the establishment and maintenance of a debt service reserve fund. Additional covenants include a restriction on the creation of additional liens on the Center's property, a restriction on the issuance of additional debt, and a requirement that net income available for debt service must exceed 125% of the debt service in the same year.

The following schedule shows future long-term maturities by year:

2015	\$	9,461
2016		5,366
2017		5,777
2018		6,155
2019		6,587
Thereafter		<u>326,755</u>
	\$	<u><u>360,101</u></u>

### (9) Retirement Plan

The Center has a defined-contribution plan for its salaried employees. Employees are generally eligible after one year of service. The Center contributes 7% of each employee's compensation up to the Social Security wage base limit and 12% on compensation above that limit. For certain management employees, the Center contributes 10% of compensation up to the Social Security wage base limit and 15% above the limit.

Retirement plan contributions for the years ended June 30, 2014 and 2013 was \$13,473 and \$13,207, respectively.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

#### **(10) Perpetual Trusts and Charitable Remainder Trusts**

The Center is the beneficiary of irrevocable perpetual trusts and charitable remainder trusts for which the Center is not the trustee. These funds held in trust by others represent resources neither in the possession nor under the control of the Center and are administered by outside trustees. When the Center is notified of the existence of an irrevocable perpetual trust, the Center recognizes its beneficial interest in the outside trust at fair value as a contribution. The contribution is classified as an increase in permanently restricted net assets based on restrictions placed by the donor. The changes in the fair value of the irrevocable perpetual trusts are reflected as investment changes restricted by donors, in permanently restricted net assets on the statements of activity.

When the Center is notified of an irrevocable charitable remainder trust for which it is not the trustee, the Center recognizes its beneficial interest in the outside trust as a contribution at fair value, which is measured as the present value of the estimated expected future benefits to be received. The contribution is classified as an increase in temporarily restricted net assets based on restriction placed by the donor upon the Center's beneficial interest in the assets. Periodic adjustments recorded to the beneficial interest to reflect changes in the fair value, life expectancy, and discount rate are recognized based on information from outside trustees. Any charitable remainder trusts for which the Center is not the trustee are reflected as a receivable from trusts and are included in other receivables in the accompanying consolidated balance sheets. These amounts as of June 30, 2014 and 2013 were \$1,952 and \$1,849, respectively.

#### **(11) Annuities**

The Center administers, through a third party, gift annuities for which it is obligated to make periodic distributions to designated beneficiaries. When contributed assets are initially received, the assets are recorded at fair value within the investments balance, and contribution revenue is recorded equal to the value of the contributed assets received less the annuity liability. The present value of the payments due to the beneficiaries totaled \$3,914 and \$4,344 at June 30, 2014 and 2013, respectively. The annuity liability is revalued annually based upon actuarially computed present values. Present values are based on life expectancy and discount rates range between 4% and 10%. The Center maintains segregated funds that exceed the actuarial value of the annuity liability as required by state law. The gift annuity payable is recorded in accrued liabilities.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

#### (12) Commitments and Contingencies

##### (a) Operating Leases

Certain equipment and facilities utilized by the Center in its operations are leased. The related future minimum rental payments for these operating leases with noncancelable terms in excess of one year as of June 30, 2014 are as follows:

2015	\$	3,226
2016		2,731
2017		2,801
2018		1,818
2019		1,518
Thereafter		<u>7,024</u>
	\$	<u>19,118</u>

Rental expense for all operating leases for the years ended June 30, 2014 and 2013 was \$4,478 and \$4,866, respectively.

In conjunction with purchase and renovation of office and lab space in the 1100 Eastlake Building, the Center gave notice on March 31, 2011 of its intent to terminate its lease obligation for the 1616 Eastlake Building. Under the terms of the operating lease, beginning on October 1, 2012, the Center reduced the amount of space leased from approximately 106,000 net rentable square feet to approximately 40,000 net rentable square feet. The lease term for most of the 40,000 net rentable square feet extends through September 30, 2017. On May 11, 2012, the Center entered into a lease amendment to reduce the amount of space leased by approximately 13,000 net rentable square feet to approximately 27,000 net rentable square feet. The Center expects to continue to utilize the office portion of this space and has subleased the lab portion of this space as of June 30, 2014.

In 2011, the Center recorded a payable for \$3,101 and an expense associated with the anticipated shortfall to be generated from sublease revenue compared with the obligated lease payments included in the amounts shown above. In 2012, the payable was reduced to \$1,351 to reflect modifications to future cash flows resulting from the May 11, 2012 amendment and the sublease of a portion of the remaining leased space.

##### (b) Litigation and Compliance with Laws and Regulations

The Center is involved in litigation and regulatory investigations arising in the normal course of its business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the Center's future financial position or results from operations.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

The research industry is subject to numerous federal, state, and local laws and regulations. Some of these laws govern licensure, accreditation, and government program participation requirements. Government agencies are actively conducting investigations concerning possible violations of these statutes and regulations by research facilities. Violations of these laws and regulations could result in expulsion from government programs, together with the imposition of significant fines and penalties. Management believes that the Center is in material compliance with all applicable laws and regulations. Compliance with laws and regulations is subject to future government review and interpretation of such laws and regulations as well as regulatory actions unknown or unasserted at this time.

**(c) Contingent Liability**

The Center received federal grant funding for a portion of the construction of its South Lake Union Campus. Because the Center received federal grant funding for a portion of this facility, the government retains an interest in the net proceeds received if the facility is sold. The Center has not recorded any liability related to this interest as it is contingent upon the sale of the facility, and management has determined the probability of this transaction occurring to be remote.

**(d) United States Agency for International Development (USAID) Grant**

The USAID awarded a construction grant of \$1,400 to the Center to begin to build a new research and medical facility for HCRIU in Kampala, Uganda. The grant has a cost-share arrangement that requires the Center to fund an additional \$1,500 during the grant award period. Construction began in fiscal year 2014 and is expected to be completed in fiscal year 2015 at a total project cost of \$9,100.

**(13) Professional Liability Insurance**

The Center has claims-made professional and general liability insurance for 2014 and 2013. The Center has accrued an actuarial estimate of unreported instances and claims as of June 30, 2014, which is included in accounts payable.

**(14) Related-Party Transactions**

In June 1998, the SCCA was formed. The SCCA is a joint venture between the University of Washington Academic Medical Center (UWMC), Children's Hospital and Regional Medical Center (now Seattle Children's Hospital (Seattle Children's)), and the Center. As a separately incorporated nonprofit corporation, the SCCA is organized for the purpose of developing and offering a comprehensive program of integrated cancer care services in the Northwest that will enhance the cancer research, teaching, and clinical programs of the Center, UWMC, and Seattle Children's. The SCCA is one of several Medicare-designated cancer hospitals in the United States. Members of the SCCA share equally in capital contributions and in the results of operations. The SCCA began operations in January 2001. The SCCA coordinates adult inpatient services with the UWMC and pediatric inpatient services with Seattle Children's, while operating its own ambulatory cancer care service facility. The Center is accounting for its interest in the SCCA under the equity method.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

Under the terms of the Members' Agreement, the Center has certain financial obligations to the SCCA, including funding its share of capital contributions. From 1998 through 2001, the Center contributed a total of \$13,562 in cash capital contributions, which have been recorded as beneficial interest in assets of SCCA on the consolidated statements of financial position. The Center's obligations to the SCCA were fully paid as of June 30, 2001. In addition, in 2001 the Center contributed its existing outpatient cancer care program valued at \$12,124, equipment, supplies, and other assets valued at \$1,800, and a ground lease valued at \$3,600 to the SCCA. The Center records the amortization of these contributed assets in investment income.

The following is a summary of the SCCA's financial position and results as of and for the years ended June 30, 2014 and 2013:

	<b>2014</b>	<b>2013</b>
Assets	\$ 488,899	440,985
Liabilities	\$ 170,708	157,923
Net assets	318,191	283,062
Total liabilities and net assets	\$ 488,899	440,985
	<b>2014</b>	<b>2013</b>
Revenues	\$ 435,228	393,731
Less expenses	(408,155)	(363,819)
Plus nonoperating income (loss)	7,689	(23,334)
Excess of revenues over expenses	34,762	6,578
Net assets released from restriction for capital	270	85
Grant contributions restricted for capital acquisition	—	740
Net change in unrealized (losses) gains on investments	(26)	13,253
Increase in unrestricted net assets	\$ 35,006	20,656

The Center has entered into service agreements to provide support services to the SCCA. The service agreements are for administrative services, facilities usage, and patient care housing. The Center recognized \$15,771 and \$12,340 of other income for the years ended June 30, 2014 and 2013, respectively, as a result of these agreements.

The Center recognized other income (see below) for the years ended June 30, 2014 and 2013, respectively, for fees associated with licenses, data collection, and research and development services provided by the Center to the SCCA.

## FRED HUTCHINSON CANCER RESEARCH CENTER

### Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

#### (15) Other Income

The Center has entered into inpatient service agreements with UWMC, Seattle Children's, and the SCCA through 2014 for which the Center receives various payments related to research and development support, data collection and analysis, physician assistant services, consulting services, and license rights to use the Center's name in connection with the inpatient cancer services program. Fees for services during the years ended June 30, 2014 and 2013 from UWMC total \$10,261 and \$11,979, respectively, from Seattle Children's total \$1,204 and \$1,135, respectively, and from the SCCA total \$6,346 and \$6,203, respectively. Of these amounts, \$5,711 and \$6,517 are included in other receivables as of June 30, 2014 and 2013, respectively.

#### (16) Accounting for Derivative Instruments and Hedging Activities

Accounting principles require that every derivative instrument (including certain derivative instruments embedded in other contracts) be recorded on the balance sheet as either an asset or liability measured at its fair value. These principles require that changes in the derivative instrument's fair value be recognized currently.

##### (a) Interest Rate Swaps

In October 2008, the Center entered into two interest rate swaps to replace the swaps that were terminated. One of the swaps was associated with the Series 2000 Bonds (Series 2000 Replacement Swap) and one is associated with the Series 2001A Bonds (Series 2001A Replacement Swap). The notional amount, timing of principal payments, and timing of interest payments for each of the Replacement Swaps are similar to the terms of the bonds with which they are associated. In the case of the Series 2000 Replacement Swap, the interest rate paid by the Center was fixed at 5.19% while the counterparty pays the Center an indexed rate plus 20 basis points. In the case of the Series 2001A Replacement Swap, the interest rate paid by the Center was fixed at 4.97% while the counterparty pays the Center an indexed rate plus 0.20%. Upon entering into the Replacement Swaps, the Center received a payment of \$7,150 for the Series 2000 Replacement Swap and \$7,690 for the Series 2001A Replacement Swap from the counterparty. These payments were recorded as deferred credits on cash flow hedges on the balance sheet. The fair value is the estimated amount the bank would receive or pay to terminate the swap agreement at the reporting date, taking into account current interest rates and the current creditworthiness of the swap counterparties. The fair value of the Series 2000 Replacement Swap included in liabilities was \$11,961 at June 30, 2014 and \$12,802 at June 30, 2013. The fair value of the Series 2001A Replacement Swap included in liabilities was \$16,825 at June 30, 2014 and \$17,433 at June 30, 2013. The fair value of the swap instruments will change in future time periods as interest rates change and as the time period remaining for the hedged transaction shortens. Provided that the Center holds the swaps to maturity, the value of the derivative will be zero.

**FRED HUTCHINSON CANCER RESEARCH CENTER**

Notes to Consolidated Financial Statements

June 30, 2014 and 2013

(In thousands)

**(b) *Amendment to Series 2001A Replacement Swap***

In May 2011, the Center amended the Series 2001A Replacement Swap to change the rate paid by the counterparty from a tax-exempt indexed rate plus 0.20% to 67% of three month LIBOR plus 0.64%. All other terms of the Series 2001A Replacement Swap, including notional amount, timing, and amount of principal payments remain unchanged.

**(c) *Collateral Posted with Swap Counterparty***

The replacement swap agreements contain terms that require the Center to post collateral with the counterparty if the mark-to-market amount to terminate the Series 2000 Replacement Swap and the Series 2001A Replacement swap exceeds \$40,000. As of June 30, 2014 and 2013, no collateral was needed nor posted with the counterparty.

**(17) Subsequent Events**

The Center evaluated subsequent events from June 30, 2014 to October 31, 2014 the date on which these financial statements were issued.

On July 24, 2014, the Center issued through the Authority \$4,435 of tax-exempt revenue bonds Series 2014 (2014 Bonds). The 2014 Bonds are variable rate bonds used to refund the 2007 Bond. The 2014 Bonds were issued under a private placement with US Bank, and all interest and principal payments are made directly to the bank.





KPMG LLP  
Suite 2900  
1918 Eighth Avenue  
Seattle, WA 98101

**Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards***

The Board of Trustees  
Fred Hutchinson Cancer Research Center:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Fred Hutchinson Cancer Research Center (the Center), which comprise the consolidated balance sheets as of June 30, 2014 and 2013, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 31, 2014.

**Internal Control over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the Center's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion<sup>3</sup> on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Center's internal control. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Center's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Center's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

**KPMG LLP**

October 31, 2014



KPMG LLP  
Suite 2900  
1918 Eighth Avenue  
Seattle, WA 98101

**Independent Auditors' Report on Compliance for Each Major Program;  
Report on Internal Control Over Compliance; and Report on Schedule of  
Expenditures of Federal Awards Required by OMB Circular A-133,  
*Audits of States, Local Governments, and Non-Profit Organizations***

The Board of Trustees  
Fred Hutchinson Cancer Research Center:

**Report on Compliance for Each Major Federal Program**

We have audited Fred Hutchinson Cancer Research Center's (the Center) compliance with the types of compliance requirements described in the OMB Circular A-133 Compliance Supplement that could have a direct and material effect on each of the Center's major federal programs for the year ended June 30, 2014. The Center's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

***Management's Responsibility***

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

***Auditors' Responsibility***

Our responsibility is to express an opinion on compliance for each of the Center's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Center's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the Center's compliance.

***Opinion on Each Major Federal Program***

In our opinion, the Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2014.



## **Report on Internal Control Over Compliance**

Management of the Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Center's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.



### **Report on Schedule of Expenditures of Federal Awards Required by OMB Circular A-133**

We have audited the consolidated financial statements of the Center as of and for the year ended June 30, 2014, and have issued our report thereon dated October 31, 2014, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by OMB Circular A-133 and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

*KPMG LLP*

October 31, 2014

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Expenditures
DIRECT RESEARCH AND DEVELOPMENT AWARDS		
DEPARTMENT OF HEALTH AND HUMAN SERVICES / NATIONAL INSTITUTES OF HEALTH		
N/A	NATIONAL CANCER INSTITUTE	\$ 10,828,450
93.393	NATIONAL CANCER INSTITUTE	23,382,097
93.394	NATIONAL CANCER INSTITUTE	10,625,189
93.395	NATIONAL CANCER INSTITUTE	22,027,889
93.396	NATIONAL CANCER INSTITUTE	5,306,346
93.397	NATIONAL CANCER INSTITUTE	18,181,441
93.398	NATIONAL CANCER INSTITUTE	3,059,918
93.399	NATIONAL CANCER INSTITUTE	3,049,255
93.701	NATIONAL CANCER INSTITUTE	569,159
93.855	NATIONAL CANCER INSTITUTE	1,828,122
93.307	NATIONAL CENTER ON MINORITY HEALTH & DIS	499,803
93.279	NATIONAL INSTITUTE ON DRUG ABUSE	1,746,179
93.701	NATL CENTER FOR RESEARCH RESOURCES	(6,983)
N/A	NATL HEART, LUNG AND BLOOD INSTITUTE	12,429,186
93.701	NATL HEART, LUNG AND BLOOD INSTITUTE	20,620
93.837	NATL HEART, LUNG AND BLOOD INSTITUTE	6,889,969
93.838	NATL HEART, LUNG AND BLOOD INSTITUTE	1,722,449
93.839	NATL HEART, LUNG AND BLOOD INSTITUTE	4,426,483
93.172	NATL HUMAN GENOME RESEARCH INSTITUTE	3,421,287
93.310	NATL HUMAN GENOME RESEARCH INSTITUTE	598,725
N/A	NATL INST OF ALLERGY AND INFECTIOUS DSE	1,368,196
93.855	NATL INST OF ALLERGY AND INFECTIOUS DSE	90,709,544
93.856	NATL INST OF ALLERGY AND INFECTIOUS DSE	253,307
93.846	NATL INST OF ARTH AND MUSC SKIN AND DSE	1,620,163
93.172	NATL INST OF CHILD HEALTH & HUMAN DEV	614,915
93.865	NATL INST OF CHILD HEALTH & HUMAN DEV	1,669,728
93.121	NATL INST OF DENTAL CRANIO RESEARCH	480,993
93.847	NATL INST OF DIAB AND DIGST AND KDNY DSE	4,186,579
93.849	NATL INST OF DIAB AND DIGST AND KDNY DSE	295,285
93.113	NATL INST OF ENVIRONMENTAL HEALTH SCI	2,168,310
93.839	NATL INST OF GENERAL MEDICAL SCIENCES	35,071
93.859	NATL INST OF GENERAL MEDICAL SCIENCES	9,213,681
93.242	NATL INST OF MENTAL HEALTH	227,221
93.853	NATL INST OF NEURO DISORDERS AND STROKE	2,615,100
93.173	NATL INST ON DEAFNESS AND COMM DISORDER	530,704
93.286	NAT'L INSTITUTE OF BIOMED IMAGING & BIOE	472,867
93.866	NATL INSTITUTE ON AGING	2,300,138
93.310	OFFICE OF THE DIRECTOR, NIH	1,451,356
93.351	OFFICE OF THE DIRECTOR, NIH	371,262
DIRECT FUNDING / OTHER FEDERAL AGENCIES		
N/A	DEPARTMENT OF HEALTH AND HUMAN SERVICES	182,575
N/A	DEPARTMENT OF VETERANS AFFAIRS	68,072
12.420	DEPARTMENT OF DEFENSE	2,010,912
12.431	DEPARTMENT OF DEFENSE	66,255
12.910	DEPARTMENT OF DEFENSE	495,566
47.049	NATIONAL SCIENCE FOUNDATION	187,319
47.070	NATIONAL SCIENCE FOUNDATION	288,055
47.074	NATIONAL SCIENCE FOUNDATION	297,363
98.006	AGENCY FOR INTERNATIONAL DEVELOPMENT	1,050,161
GRANT TOTAL -DIRECT RESEARCH AND DEVELOPMENT		\$ 255,836,279

FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards  
Year ended June 30, 2014

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period end	Expenditures
	Pass-Through Funds – Department of Health and Human Services and Other Federal Agencies:				
	ADAPTIVE BIOTECHNOLOGIES CORPORATION				
93.839	CORRELATING TCR DIVERSITY TO IMMUNE RECONSTITUTION AFTER CORD BLOOD TRANSPLANT	FHCRC106969-02	2013-09-10	2014-11-30	\$ 56,737
	ALBERT EINSTEIN COLLEGE OF MEDICINE				
N/A	F AND A SUPPORT TO 211461: OBESITY RELATED PATHWAYS AND RISK OF BENIGN PROLIFERATIVE BREAST DISEASE	9-526-0128	2012-10-01	2013-09-30	2,258
93.393	SERUM LEVELS OF EGF-R SIGNALING-NETWORK ACTIVATORS/INHIBITOR AND RISK OF LUNG CANCER	9-526-6923	2012-09-01	2013-08-31	861
93.853	INTERNATIONAL STROKE GENETICS CONSORTIUM STUDY	331082	2012-07-01	2013-06-30	17,883
93.853	INTERNATIONAL STROKE GENETICS CONSORTIUM STUDY	9-526-8580	2011-07-01	2012-06-30	(17,883)
93.866	EVIDENCE FOR ESTABLISHING OPTIMUM PROTEIN INTAKE IN OLDER ADULTS	310455	2013-02-01	2014-01-31	20,977
	ARIZONA STATE UNIVERSITY				
93.172	CEGS TECH: INTEGRATE BIOLOGICALLY-ACTIVE MICROSYSTEMS	13-119	2012-08-01	2013-07-31	2,429
93.393	A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY	13-013	2012-09-01	2013-08-31	9,864
93.393	A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY	14-346	2013-09-01	2014-08-31	91,799
93.393	A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY/CORE 2	13-012	2012-09-01	2013-08-31	13,881
93.393	A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY/CORE 2: MATERIALS CORE	14-345	2013-09-01	2014-08-31	98,419
	BASTYR UNIVERSITY				
93.213	BASTRY/UW ONCOMYCOLOGY TRANSLATIONAL RESEARCH CENTER	H34B11-03	2012-09-01	2013-08-31	4,804
93.213	BASTRY/UW ONCOMYCOLOGY TRANSLATIONAL RESEARCH CENTER	H34B11-03 (4)	2013-09-01	2014-08-31	10,784
93.213	BREAST CANCER INTEGRATIVE ONCOLOGY: PROSPECTIVE MATCHED CONTROLLED OUTCOMES STUDY	H33B11-01 (4)	2013-05-01	2014-04-30	266,764
93.213	BREAST CANCER INTEGRATIVE ONCOLOGY: PROSPECTIVE MATCHED CONTROLLED OUTCOMES STUDY	H33B11-01 (5)	2014-05-01	2015-04-30	41,638
	BATELLE MEMORIAL INSTITUTE				
N/A	CENTER FOR BIOLOGICAL FUTURES	329889	2012-05-07	2013-04-30	(1,028)
	BAYLOR COLLEGE OF MEDICINE				
93.393	ADVANCED GLYCATION END PRODUCTS AND RISK OF PANCREATIC CANCER	5600955946	2013-09-20	2015-07-31	57,872
93.393	ADVANCED GLYCATION END PRODUCTS, THE RECEPTOR, AND COLORECTAL CANCER RISK IN WOMEN	101537407	2011-09-01	2013-08-31	2,050
93.395	ADULT NEUROBEHAVIORAL LATE EFFECTS OF PEDIATRIC LOW GRADE BRAIN TUMORS	5600476674	2009-06-01	2014-04-30	14,976
	BECKMAN RESEARCH INSTITUTE-CITY OF HOPE				
93.393	ROLE OF GENETIC SUSCEPTIBILITY IN THERAPY-RELATED MALIGNANCIES	22175.915021.6693	2012-12-01	2013-11-30	9,796
93.393	ROLE OF GENETIC SUSCEPTIBILITY IN THERAPY-RELATED MALIGNANCIES	22175.915021.6693	2013-12-01	2014-11-30	11,657
93.397	CITY OF HOPE LYMPHOMA SPORE	22679.916790.6693	2013-09-06	2014-08-31	60,219
93.397	CITY OF HOPE LYMPHOMA SPORE	50127.916768.68	2012-09-01	2013-08-31	1,674
	BENAROY A RESEARCH INSTITUTE				
93.855	IMMUNE TOLERANCE NETWORK	FY14ITN025	2014-05-01	2015-01-31	51,215
	BETH ISRAEL DEACONESS MEDICAL CENTER				
93.396	ANDROGEN RECEPTOR ACTION IN CASTRATION RESISTANT PROSTATE CANCER - PROJECT 3	01026707	2013-05-24	2014-04-30	84,350
93.396	ANDROGEN RECEPTOR ACTION IN CASTRATION RESISTANT PROSTATE CANCER: PROJECT 1	01026705A	2013-05-24	2014-04-30	341,637
93.396	ANDROGEN RECEPTOR ACTION IN CASTRATION RESISTANT PROSTATE CANCER: CORE A	01026705B	2013-05-24	2014-04-30	15,916
93.396	CORE A: ADMINISTRATIVE/CLINICAL-BIOSTATISTICS	01027362	2014-05-01	2015-04-30	2,705
93.396	PROJECT 1: STEROID METABOLISM IN CASTRATION-RESISTANT PROSTATE CANCER	01027365	2014-05-01	2015-04-30	83,182
93.866	BREAST CANCER RISK FACTORS AMONG WOMEN AGED 75 AND OLDER	01026387	2013-04-01	2013-09-30	4,016
	BIOFORMATIX				
93.393	ULTRASENSITIVE BIOASSAYS USING PALLADIUM CATALYZED CHEMICAL AMPLIFICATION	NA	2011-09-02	2014-02-28	769
	BOSTON UNIVERSITY				
93.172	METHODS FOR THE ANALYSIS AND INTEGRATIONS OF NEXT-GENERATION SEQUENCING	4500000944	2012-03-01	2015-02-28	95,692
	BRIGHAM & WOMEN'S HOSPITAL				
N/A	METABOLOMICS OF CHD IN THE WHI	109102	2014-03-29	2015-03-28	3,509
93.837	RACIAL/ETHNIC DIFFERENCES IN 25(OH)D AND PTH LEVELS AND CVD AMONG WOMEN	109452	2013-08-01	2013-11-30	5,274
	BROAD INSTITUTE				
93.394	PROTEO-GENOMIC DISCOVERY, PRIORITIZATION AND VERIFICATION OF CANCER BIOMARKERS	6610200-5500000391	2011-08-26	2012-07-31	(8)
93.394	PROTEO-GENOMIC DISCOVERY, PRIORITIZATION AND VERIFICATION OF CANCER BIOMARKERS	6610202-5500000391	2012-08-01	2013-07-31	503,241
93.394	PROTEO-GENOMIC DISCOVERY, PRIORITIZATION AND VERIFICATION OF CANCER BIOMARKERS	6610203-5500000391	2013-08-01	2014-07-31	1,193,765
	BROWN UNIVERSITY				
93.113	AMBIENT AIR POLLUTION AND INCIDENT STROKE	00000541	2012-07-01	2015-03-31	11,923
	CASE WESTERN RESERVE UNIVERSITY				
93.399	GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RESS07597	2012-09-01	2013-08-31	33,857
93.399	GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RESS08419	2013-09-01	2014-08-31	102,136
	CEDARS-SINAI MEDICAL CENTER				
93.396	PROSTATE CANCER BONE METASTASIS: BIOLOGY AND TARGETING/PATHOLOGY AND LABORATORY SUPPORT CORE	0000981041	2013-08-01	2014-07-31	7,028
93.396	PROSTATE CANCER BONE METASTASIS: BIOLOGY AND TARGETING/PATHOLOGY AND LABORATORY SUPPORT CORE	894218	2012-08-01	2013-07-31	636
	CLEVELAND CLINIC LERNER COLLEGE OF MED				
93.396	NON-NEOPLASTIC CELL TYPES DICTATE GLIOMAGENESIS	409-SUB	2013-09-01	2014-08-31	36,848
	COALITION OF CANCER COOP GROUPS, INC				
N/A	INFRASTRUCTURE FOR TRANSPLANT PROTOCOLS FOR HIV PLUS PATIENTS WITH HEMATOLOGIC MALIGNANCIES	N02-CM-62212	2012-09-01	2013-06-30	3,101
N/A	S05 PHASE III PROSPECTIVE RANDOMIZED COMPARISON OF DEPOT OCTREOTIDE PLUS INTERFERON ALPHA VERSUS DEPOT OCTREOTIDE PLUS BEVACIZUMAB (NSC #704865) IN ADVANCED, POOR PROGNOSIS CARCINOID PATIENTS	CTS-U - STATISTICAL S	2012-07-01	2013-06-30	(153)
	COLUMBIA UNIVERSITY MEDICAL CENTER				
93.067	RAPID SCALE UP OF HIV/AIDS CARE AND TREATMENT SERVICES IN KINGDOM OF SWAZILAND	5U2GPS002005-04	2012-09-30	2013-09-29	65,016
93.067	RAPID SCALE-UP OF HIV/AIDS CARE AND TREATMENT SERVICES IN KINGDOM OF SWAZILAND	U2GPS002005-05	2013-09-30	2015-03-31	125,628
93.395	USING SWOON-MEDARE DATABASE TO EVALUATE LONG-TERM TOXICITIES OF CANCER SURVIVORS	GG007536	2013-02-15	2015-01-31	13,348
93.847	ANALYSIS OF NGAL METABOLISM IDENTIFIES A THERAPY FOR IRON OVERLOAD	1 (GG006245)	2011-09-01	2013-08-31	1,552
	IRON LIPOCALIN NGAL IN KIDNEY DISEASE	GG006353	2011-12-12	2013-11-30	53,362
	COURTESY ASSOCIATES				
N/A	BURKITT LYMPHOMA TRIAL NETWORK	GS-23-F-0274M-59	2013-01-01	2013-09-30	81,785
	DANA-FARBER CANCER INSTITUTE				
93.393	PROSPECTIVE COHORT COLLABORATIVE IN PANCREATIC CANCER EPIDEMIOLOGY AND PATHOGENESIS	1144807	2012-09-01	2013-08-31	5,418
93.397	EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #2	1197105	2013-09-01	2015-08-31	69,413
93.397	EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #1	1197005	2013-09-01	2015-08-31	110,718
93.397	EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #3	1197205	2013-09-01	2015-08-31	19,470
93.397	EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #4	1197405	2013-09-01	2015-08-31	18,493
93.855	FUNCTIONAL GENOMIC ANALYSIS OF THE CD8 T CELL RESPONSE TO HIV VACCINES IN HUMANS	1194803	2012-09-01	2013-08-31	64,282
93.855	FUNCTIONAL GENOMIC ANALYSIS OF THE CD8 T CELL RESPONSE TO HIV VACCINES IN HUMANS	1194804	2013-09-01	2014-08-31	157,691
	DUKE UNIVERSITY				
N/A	SCOT: A RANDOMIZED, OPEN-LABEL, PHASE II/III MULTICENTER STUDY OF HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY	HHSN272201100025C-52	2012-11-01	2013-10-31	8,708
N/A	SCOT: A RANDOMIZED, OPEN-LABEL, PHASE II/III MULTICENTER STUDY OF HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY	HHSN272201100025C-52	2013-11-01	2014-10-31	335
93.394	VALIDATION OF PROGNOSTIC AND PATHWAY SIGNATURES IN LETHAL PROSTATE CANCER	2033403	2013-09-13	2014-01-31	28,549
93.855	CHAVI-ID: OPERATIONS AND MANAGEMENT SUPPORT COMPONENT SCHARP	2031957	2012-07-15	2013-06-30	(8,202)
93.855	ENTER FOR HIV/AIDS VACCINE IMMUNOLOGY AND IMMUNOGEN DISCOVERY (CHAVI-ID)	2032660	2013-07-01	2013-09-30	31,427

FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal CFTA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period end	Expenditures
93.172	EMORY UNIVERSITY ENHANCED GENE IDENTIFICATION IN COMPLEX TRAITS USING KERNEL MACHINES	T088213	2013-09-04	2015-06-30	\$ 56,785
93.989	FOGARTY INTERNATIONAL CENTER EXPANDING INDEPENDENT RESEARCH CAPACITY IN HIV-ASSOCIATED MALIGNANCIES IN UGANDA	D43 TW009759	2014-06-01	2015-03-31	2,075
93.989	EXPANDING INDEPENDENT RESEARCH CAPACITY IN HIV-ASSOCIATED MALIGNANCIES IN UGANDA	D43 TW009759	2014-06-01	2015-03-31	1,181
93.393	GEORGETOWN UNIVERSITY OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING	RX 4442-041-FHCRC	2013-09-25	2014-08-31	26,264
93.846	VALIDATION OF PROMIS IN DIVERSE CANCER POPULATIONS	4442-007-FHCRC	2012-08-01	2014-07-31	110,871
93.172	GROUP HEALTH COOPERATIVE GENETIC DISCOVERY AND APPLICATION IN A CLINICAL SETTING: CONTINUING A PARTNERSHIP	2012119952	2012-08-01	2013-07-31	2,195
93.172	GENETIC DISCOVERY AND APPLICATION IN A CLINICAL SETTING: CONTINUING A PARTNERSHIP	2013156521	2013-08-01	2014-07-31	26,233
93.393	SYSTEMS OF SUPPORT (SOS) TO INCREASE COLON CANCER SCREENING AND FOLLOW-UP	2013154896	2013-09-01	2014-06-30	16,465
93.866	ALZHEIMER'S DISEASE PATIENT REGISTRY	2012121173	2012-09-01	2013-08-31	4,393
93.395	GYNECOLOGIC ONCOLOGY GROUP GOG AGREEMENT: FUNDS FOR CO-CHAIR OF THE GOG CERVIX COMMITTEE	CA27469-33 CERVIX CO	2013-04-01	2014-02-28	5,638
93.393	GYNECOLOGICAL ONCOLOGY GROUP H. LEE MOFFITT CANCER CENTER & RES. INST	27469-23	2004-04-01	2016-03-31	141,504
93.393	FOLLOW-UP OF OVARIAN CANCER GENETIC ASSOCIATION AND INTERACTION STUDIES (FOCI)	10-15915-03-05-G2	2012-07-01	2013-06-30	(2)
93.393	FOLLOW-UP OF OVARIAN CANCER GENETIC ASSOCIATION AND INTERACTION STUDIES (FOCI)	10-15915-04-05-G2	2013-07-01	2014-06-30	16,455
93.393	HARVARD UNIVERSITY TRANSDISCIPLINARY CANCER GENOMICS RESEARCH: POST-GWA INITIATIVE	114080-5029131	2013-07-01	2014-06-30	101,901
93.837	CIRCULATING DIETARY AND METABOLIC FATTY ACIDS, MAJOR CVD OUTCOMES AND HEALTHY AGING	114149-5061567-0009	2013-07-01	2014-06-30	137,187
93.393	HEALTH RESEARCH INC FLAXSEED EFFECTS ON HORMONES AND LIGNANS: ROLE OF RACE, GENES, AND GUT MICROBIOME	83-01	2012-09-25	2015-08-31	176,592
N/A	HENRY M. JACKSON FOUNDATION STATISTICAL AND DATA MANAGEMENT SUPPORT FOR ANALYSIS RELATED TO VACCINE TRIAL (RV144) AND ASSOCIATED TRIALS	694251	2010-02-01	2013-09-30	102,925
N/A	STATISTICAL AND DATA MANAGEMENT SUPPORT FOR ANALYSIS RELATED TO VACCINE TRIAL (RV144) AND ASSOCIATED TRIALS	792087	2013-10-01	2014-09-30	266,650
93.865	INDIANA UNIVERSITY-PURDUE UNIVERSITY IND BRIDGING PEDIATRIC AND ADULT BIOMARKERS OF GRAFT-VERSUS-HOST DISEASE	IN4689628FHCRC	2013-08-01	2015-05-31	48,454
93.393	INSTITUTE FOR CANCER RESEARCH GENETIC FACTORS AND THEIR ROLE IN DETERMINING CHEMOPREVENTION EFFECTIVENESS (SELECT) AND BIOPSY OUTCOME IN A CHEMOPREVENTION COHORT (PCPT)	ELLIPSE	2013-05-01	2014-04-30	50,838
93.393	INTERNATIONAL AGENCY FOR RESEARCH ON CAN ONE-CARBON METABOLISM BIOMARKERS AND LUNG CANCER RISK	GEP/12/02	2012-01-31	2014-08-31	35,620
93.862	IOWA STATE UNIVERSITY DNA TARGETING BY TAL EFFECTORS	430-46-05A	2011-09-01	2015-04-30	97,344
12.420	JOHNS HOPKINS UNIVERSITY PROSPECTIVE EVALUATION OF INTRAPROSTATIC INFLAMMATION AND FOCAL ATROPHY AS A PREDICTOR OF RISK OF HIGH-GRADE PROSTATE CANCER AND RECURRENCE AFTER PROSTATECTOMY	2002119729	2014-01-01	2014-12-31	4,729
93.242	INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS GROUP (IMPAACT)	2001664569	2012-06-01	2013-12-31	38,225
93.393	PROSTATE CANCER SUSCEPTIBILITY: THE ICPG STUDY	2000347454	2011-09-01	2013-08-31	34,145
93.837	MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE	2001414485	2011-12-15	2014-11-30	165,674
93.855	EPIDEMIOLOGY AND ECOLOGY OF VIBRIO CHOLERAE IN BANGLADESH	2000990845	2010-06-15	2015-05-31	69,070
93.859	CENTER FOR SYSTEMS BIOLOGY OF RETROTRANSPOSITION KAISER FOUNDATION RESEARCH INSTITUTE	AWOA	2013-09-05	2013-09-06	97,861
93.393	CRN4: CANCER RESEARCH RESOURCES AND COLLABORATION IN INTEGRATED HEALTH CARE SYSTEMS	115-9341-FHCRC-01	2012-09-25	2013-08-31	10,042
93.393	CRN4: CANCER RESEARCH RESOURCES AND COLLABORATION IN INTEGRATED HEALTH CARE SYSTEMS	115-9341-FHCRC-01	2013-09-01	2014-08-31	21,595
93.865	APPROPRIATE GESTATIONAL WEIGHT GAIN IN OVERWEIGHT/OBESE WOMEN	115-9446-1	2014-03-01	2015-02-28	11,611
N/A	LEIDOS BIOMEDICAL RESEARCH, INC AMC HIV POSITIVE TUMOR MOLECULAR CHARACTERIZATION PROJECT	13ST4122	2013-07-02	2015-03-31	189,755
N/A	EXPANDING CAPACITY FOR INFECTION-RELATED CANCER RESEARCH BY EXAMINING THE CONTRIBUTION OF VIRAL GENOMIC DIVERSITY TO THE CLINICAL MANIFESTATIONS OF CANCER IN UGANDA	14X0067	2014-03-07	2015-03-06	8,244
N/A	FHCRC ORALCHIP STUDY	12X8531 - ST01	2012-11-07	2014-12-31	7,030
N/A	GENERATING EMPIRICALLY DETERMINED PROTEIN SIGNALING NETWORKS TO INTERPRET TCGA TUMOR PROFILES	14X8040	2014-04-04	2015-04-03	13,519
N/A	HUMAN TO MOUSE LUNG CANCER CHEMOPREVENTION PILOT STUDIES	12X8532	2012-08-16	2013-08-15	15,428
N/A	REPOSITORY OF MOUSE TISSUES AND PLASMA	12X8485	2012-07-01	2015-06-30	19,674
N/A	TRANSLATION STATE PROFILING IN CANCER	12ST1102	2012-10-29	2013-09-30	116,117
93.855	MAGEE-WOMEN'S RESEARCH INSTITUTE & FOUND MICROBICIDE TRIALS NETWORK	9246	2012-06-01	2013-12-31	124,010
93.855	MICROBICIDE TRIALS NETWORK: COMPLETED TRIAL/LAB ANALYSES	9264	2012-06-01	2013-12-31	257,524
93.855	MICROBICIDE TRIALS NETWORK: MTN - BEHAVIORAL ANALYSIS	9288	2014-01-01	2014-11-30	485,112
93.855	MICROBICIDE TRIALS NETWORK: MTN-003	9263	2012-06-01	2013-12-31	245,774
93.855	MICROBICIDE TRIALS NETWORK: MTN-003	9308	2014-01-01	2014-11-30	164,651
93.855	MICROBICIDE TRIALS NETWORK: MTN-023	9309	2014-01-01	2014-11-30	156,442
93.855	MICROBICIDE TRIALS NETWORK: MTN-024	9310	2014-01-01	2014-11-30	90,939
93.855	MTN-014: A PHASE 1 CROSSOVER TRIAL EVALUATING THE PHARMACOKINETICS OF TENOFOVIR REDUCED-GLYCERIN 1% GEL IN THE RECTAL AND VAGINAL COMPARTMENTS IN WOMEN	9311	2014-01-01	2014-11-30	49,198
93.393	MASSACHUSETTS GENERAL HOSPITAL COMPARATIVE MODELING OF LUNG CANCER CONTROL POLICIES	217238	2012-09-01	2013-08-31	68,194
93.393	COMPARATIVE MODELING OF LUNG CANCER CONTROL POLICIES	217238	2013-09-01	2014-08-31	151,028
93.393	CONTROLLING ESOPHAGEAL CANCER IN THE US: A COLLABORATIVE MODELING PROJECT	217155	2013-09-01	2014-08-31	158,782
93.393	ESOPHAGEAL CANCER IN THE US: A COMPARATIVE MODELING PROJECT	217155	2012-09-01	2013-08-31	26,007
93.393	MAYO CLINIC PROSTATE CANCER SUSCEPTIBILITY: THE ICPG STUDY	63289773	2013-09-01	2014-08-31	49,791
93.855	BENCHMARKING AND STANDARDIZING HIGH DIMENSIONAL SINGLE CELL DATA ANALYSIS METHODS	63484624	2012-07-01	2014-06-30	63,676
93.855	ENABLING ADVANCED HIGH AND LOW LEVEL ANALYTICS FOR LUMINEX TECHNOLOGY	63374228	2013-10-01	2014-09-30	93,048
93.855	ENABLING ADVANCED HIGH AND LOW LEVEL ANALYTICS FOR LUMINEX TECHNOLOGY	63484622	2012-10-01	2014-06-30	82,856
93.855	HPC DATABASE INFRASTRUCTURE	63484621	2012-10-01	2014-06-30	9,214
93.855	INNATE PREDICTORS OF ADAPTIVE BCG AND HBV VACCINE-INDUCE RESPONSES IN BANGALORE ADOLESCENTS	63410674	2013-07-01	2014-06-30	17,320
93.855	INTEGRATION OF HIPC DATA TO IDENTIFY COMMON SIGNATURES OF INFLUENZA VACCINATION RESPONSES	63551928	2014-01-01	2014-12-31	5,858
93.855	STANDARDIZATION OF FLOW CYTOMETRY DATA ANALYSIS USING LYOPATES AND FITMAN MARKER PANELS	63484623	2012-12-01	2014-06-30	12,327



FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award number	Award period begin	Award period end	Expenditures
93.855	UNBIASED FUNCTIONAL PROFILING OF THE MUCOSAL-ASSOCIATED INVARIANT T CELL RESPONSE FOLLOWING MALARIA INFECTION	63512661	2013-07-01	2015-03-31	\$ 19,209
N/A	NATIONAL MARROW DONOR PROGRAM				
93.837	INDIVIDUALIZED CARE PLANS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVOR	206331	2013-09-01	2014-09-30	64,874
93.839	RDSAFE: A MULTICENTER STUDY OF HEMATOPOIETIC STEM CELL DONOR SAFETY AND QUALITY OF LIFE	18817	2010-01-01	2014-09-30	675
93.399	TRANSPLANT CENTER CLINICAL STUDY AGREEMENT	NA	2006-10-10	2015-06-30	116,846
93.399	NATL SURG ADJ BREAST & BOWEL PRJ FNDN				
93.399	NSABP PREVENTION MAIN MEMBER	PUG-YR28	2013-06-01	2014-07-31	39,021
93.399	NSABP TREATMENT PROTOCOLS FEDERAL MASTER PURCHASED SERVICES AGREEMENT	TFED-247	2006-02-01	2014-08-31	39,485
93.394	NEW YORK UNIVERSITY				
93.394	CHILEAN-AMERICAN MESOTHELIOMA BIOMARKER PROJECT	13-A0-00-002126-01	2014-01-01	2014-06-30	53,444
93.859	CENTER FOR SYSTEMS BIOLOGY OF RETROTRANSPOSITION	AWOA	2014-06-01	2015-05-31	7,334
N/A	NORTHROP GRUMMAN SYS CORP				
N/A	HUMAN IMMUNOLOGY PROJECT CONSORTIUM DATABASE HIPC-DB_RESEARCH PORTAL	7500117318	2013-08-01	2013-09-29	48,151
N/A	HUMAN IMMUNOLOGY PROJECT CONSORTIUM DATABASE HIPC-DB_RESEARCH PORTAL		2013-09-30	2014-09-29	269,392
N/A	OHIO STATE UNIVERSITY RESEARCH FOUNDATION				
N/A	INTRACEREBRAL HEMORRHAGE IN WHI (A5438)	RF01351626	2014-02-01	2014-04-14	7,941
N/A	NOVEL PREDICTORS OF EXCESS MORTALITY IN WOMEN WITH RHEUMATOID ARTHRITIS	RF01314090	2013-03-06	2013-09-30	2,877
93.701	WHI SEQUENCING PROJECT (WHISP)	60028291	2010-08-01	2013-03-31	4,886
N/A	OREGON HEALTH & SCIENCE UNIVERSITY				
N/A	SWOG S1204: A SERO-EPIDEMIOLOGIC SURVEY AND COST-EFFECTIVENESS STUDY OF SCREENING FOR HIV, HBV AND HCV AMONG NEWLY DIAGNOSED CANCER PATIENTS	1004230_FHCRC	2013-08-01	2015-07-31	34,741
93.395	CANCER CONTROL AND PREVENTION BIostatISTICS CORE	1003772_FHCRC_ANDERS	2013-06-01	2015-05-31	554,731
93.395	PCPT-SELECT STATISTICAL CENTER COMBINED ACTIVITIES	1003772_FHCRC_TANGEN	2013-06-01	2015-05-31	313,175
93.395	SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT	1004031	2013-07-01	2014-02-28	11,715
93.395	SWOG SYMPTOM CONTROL AND QUALITY OF LIFE COMMITTEE CO-CHAIR	1003772_FHCRC_MOINPO	2013-06-01	2014-07-31	23,287
93.701	SOUTHWEST ONCOLOGY GROUP TREATMENT GRANT	1004031_FHCRC_A	2013-07-01	2014-02-28	19,044
93.855	PROGRAMMING HIV IMMUNE RESPONSE FOR BROADLY NEUTRALIZING ANTIBODIES BY VACCINATION	GPRC00816A2	2013-07-01	2015-06-30	70,618
93.855	STRATEGIES TO PREVENT AND TREAT EV71 INFECTION	9004157_FHCRC_GALLOW	2013-03-01	2014-02-28	123,965
93.855	STRATEGIES TO PREVENT AND TREAT EV71 INFECTION	GVGT0104-FHCRC-GALL	2012-03-01	2013-02-28	—
N/A	SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN	AWOA	2014-03-01	2015-02-28	10,191
93.393	PRESAGE BIOSCIENCES				
93.393	SIDEPORT NEEDLE ARRAY TECHNOLOGIES FOR PRIORITIZING DRUGS FOR CANCER PATIENTS	PRESAGE STTR IIB2012	2012-05-01	2014-08-10	42,928
93.393	PRESIDENT & FELLOWS OF HARVARD COLLEGE				
93.393	GENE-ENVIRONMENT EBV INTERACTIONS IN THE ETIOLOGY OF NPC	23570-114011	2008-09-22	2015-07-31	13,016
93.855	PROGRAM FOR APPROPRIATE TECHNOLOGY/PATH				
93.855	RECOMBINASE POLYMERASE AMPLIFICATION FOR POINT-OF-CARE DIAGNOSIS OF INFANT HIV-1	NA	2011-07-01	2015-06-30	125,989
93.839	PUGET SOUND BLOOD CENTER				
93.839	HIGH DOSE GRANULOCYTE TRANSFUSIONS FOR THE TREATMENT OF INFECTION IN NEUTROPENIA THE RING STUDY	948-FHCRC-2009-01	2008-10-01	2013-08-31	9,537
N/A	RESEARCH FOUNDATION OF SUNY				
N/A	A PILOT STUDY OF URINARY BISPHENOL-A IN THE WOMEN'S HEALTH INITIATIVE	R835510	2012-11-01	2013-09-30	2,162
N/A	DEFINING AND TIMING SUDDEN CARDIAC DEATH/SUDDEN ARRHYTHMIC DEATH IN THE WOMEN'S HEALTH INITIATIVE	R835508	2012-11-01	2013-09-30	615
N/A	SYSTEMIC AND BREAST-CANCER SPECIFIC AUTOIMMUNITY IN THE WHI	R835521	2012-11-01	2013-09-30	2,390
93.855	SEATTLE BIOMEDICAL RESEARCH INSTITUTE				
93.855	IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	AWOA	2014-03-01	2014-08-31	3,451
93.855	IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	FH-16546-3	2012-09-01	2013-08-31	135,817
93.855	IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	FH-16546-4	2013-09-01	2015-08-31	109,648
93.855	OPTIMIZING HIV IMMUNOGEN-BCR INTERACTIONS FOR VACCINE DEVELOPMENT	FH-16062	2011-05-01	2014-04-30	284,507
93.855	OPTIMIZING HIV IMMUNOGEN-BCR INTERACTIONS FOR VACCINE DEVELOPMENT	FH-16062-A	2014-05-01	2014-09-30	46,783
93.113	SEATTLE CHILDREN'S HOSPITAL				
93.113	GENETICS AND THE ENVIRONMENT ASSOCIATED WITH MALE REPRODUCTION	10370SUB	2011-08-18	2013-07-31	1,653
93.113	PRENATAL ENVIRONMENTAL EXPOSURES AND REPRODUCTIVE HORMONE CONCENTRATIONS (PERCH)	11002SUB	2014-05-01	2015-04-30	1,014
93.121	ORAL PATHOGENESIS AND HOST INTERACTION OF KSHV INFECTIONS – PROJECT 4	10779SUB	2013-05-01	2014-04-30	43,897
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION – ADMINISTRATIVE CORE	10777SUB	2013-05-01	2014-04-30	28,677
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION – CLINICAL CORE	10778SUB	2013-05-01	2014-04-30	99,834
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION – CLINICAL CORE	10991SUB	2014-05-01	2015-04-30	16,682
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTIONS – ADMINISTRATIVE CORE	10989SUB	2014-05-01	2015-04-30	2,958
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTIONS – PROJECT 4	10990SUB	2014-05-01	2015-04-30	12,966
93.839	ULTRASOUND-MEDIATED GENE THERAPY FOR HEMOPHILIA B	10242SUB	2010-07-01	2014-06-30	34,254
93.847	SUBCLINICAL VIRAL INFECTION AND RENAL ALLOGRAFT INJURY	10399SUB	2011-07-01	2015-04-30	90,716
93.855	CHARACTERISTICS OF IMMUNE DEFICIENCY IN CONGENITAL BONE MARROW FAILURE SYNDROMES	10375SUB	2011-08-11	2013-07-31	1,649
93.855	CORE B OF FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY	10809SUB	2013-08-01	2014-07-31	280,934
93.855	CORE D OF FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY	10810SUB	2013-08-01	2014-07-31	274,468
93.855	FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY – CORE B	10682SUB	2012-08-07	2013-07-31	52,023
93.855	FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY – CORE D	10683SUB	2012-08-07	2013-07-31	26,368
93.855	FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY – PROJECT 2	10684SUB	2012-08-07	2013-07-31	125,125
93.855	LENTIVIRAL GENE THERAPY FOR WISKOTT-ALDRICH SYNDROME	10190SUB	2010-03-01	2014-02-28	24,512
93.855	PROJECT 2 OF FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY	10813SUB	2013-08-01	2014-07-31	378,408
93.847	SEATTLE INST FOR BIOMEDICAL & CLIN RES				
93.847	EFFECT OF DIETARY GLYCEMIC INDEX ON BETA-CELL FUNCTION	UK16-FHCRC-3	2013-06-01	2014-05-31	103,704
93.847	EFFECT OF DIETARY GLYCEMIC INDEX ON BETA-CELL FUNCTION	UK16-FHCRC-4	2014-06-01	2015-05-31	25,839
12.420	SLOAN-KETTERING INSTITUTE FOR CANCER RES				
93.393	TOWARD THE PRACTICE OF PRECISION MEDICINE: A BIOMARKER VALIDATION COORDINATING CENTER	BD516087	2013-09-30	2014-09-29	118,863
93.393	GENOME-WIDE ASSOCIATION STUDY OF RADIATION EXPOSURE AND BILATERAL BREAST CANCER	BD515757	2013-03-01	2015-02-28	134,125
93.393	MAMMOGRAPHIC DENSITY AND RISK OF CONTRALATERAL BREAST CANCER	BD515247	2012-09-19	2013-08-31	36,752
93.393	MAMMOGRAPHIC DENSITY AND RISK OF CONTRALATERAL BREAST CANCER	BD516147	2013-09-01	2014-08-31	147,126
93.396	ELUCIDATING THE FUNCTION OF THE WIDELY INACTIVATED PHOSPHATASE PTPRD IN THE MOLECULAR PATHOGENESIS OF GLOIBLASTOMA	AWOA	2014-06-01	2015-05-31	1,690
93.396	ELUCIDATING THE FUNCTION OF THE WIDELY INACTIVATED PHOSPHATASE PTPRD IN THE MOLECULAR PATHOGENESIS OF GLOIBLASTOMA	BD516003	2013-06-01	2014-05-31	16,803
93.855	SOLGENIX, INC				
93.855	BECLOMETHASONE POST EXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROME	SUB1R43A1100417FHA	2012-07-16	2013-06-30	(47)
93.855	BECLOMETHASONE POST EXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROME	SUB1R43A1100417FHA	2012-07-01	2014-06-30	60,018
93.361	ST JUDE CHILDRENS RESEARCH HOSPITAL				
93.361	EVALUATION OF CARDIOVASCULAR OUTCOMES AMONG CHILDHOOD CANCER SURVIVORS	111504030-7490973	2012-08-01	2013-07-31	2,021
93.395	EVALUATION OF CARDIOVASCULAR OUTCOMES AMONG CHILDHOOD CANCER SURVIVORS	111504040-7490974	2012-08-01	2013-07-31	1,641
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287190-7522130	2012-12-01	2013-11-30	22,404
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287190-7524262	2012-12-01	2013-11-30	406,276
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287200-7582118	2013-12-01	2014-11-30	517,374

FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period end	Expenditures
93.395	CHILDHOOD CANCER SURVIVOR STUDY (CCSS) STANFORD UNIVERSITY	111287200	2013-12-01	2014-11-30	\$ —
N/A	INTEGRATIVE GENOMICS FOR RISK OF CHD AND RELATED PHENOTYPES IN THE WOMEN'S HEALTH INITIATIVE	60541527-107901	2014-03-29	2015-03-28	4,213
N/A	VALIDATING THE CHRONIC CONDITION WAREHOUSE (CCW) ALZHEIMER'S DISEASE AND RELATED DISORDERS OF SENILE DEMENTIA IDENTIFICATION ALGORITHM IN WHI-LINKED CMS DATA	60269608	2012-09-01	2013-08-31	10,066
93.393	COLON CANCER FAMILY REGISTRY COHORT	60373227-110835-1	2013-05-01	2014-04-30	506,445
93.393	THE COLON CANCER FAMILY REGISTRY COHORT	60373227-110835-1	2014-05-01	2015-04-30	77,182
93.855	AUTOMATED COMPARISON OF FLOW DATA FROM HIV AND VACCINE INFECTED SUBJECTS	60036089-52940-A	2012-04-06	2015-03-31	41,795
93.395	SWEDISH MEDICAL CENTER SOUTHWEST ONCOLOGY GROUP (SWOG) SUBAWARD FROM SWEDISH	7701.37 NIH FHCRC	2013-01-01	2013-12-31	36,212
N/A	THE CHILDREN'S HOSPITAL OF PHILADELPHIA RISK BASED THERAPY ALLOCATION IN CHILDHOOD AML: INTEGRAL STUDIES	960417RSUB_960004061	2012-03-30	2014-06-30	419,212
93.395	CHILDREN'S ONCOLOGY GROUP CHAIR GRANT: AML COMMITTEE CHAIR	PO 960734-RSUB.ACTIV	2013-03-01	2014-02-28	7,267
93.395	MYELOID LEUKEMIA REFERENCE LABORATORY	PO960753/FP00013013	2013-03-01	2014-02-28	171,570
93.395	STUDY CHAIR: NIH COG CHAIR GRANT	FP00013087_SUB82_01	2012-03-01	2015-02-28	32,338
N/A	THE EMMES CORPORATION VRC-314 MALARIA STUDY	NA	2013-11-21	2014-01-24	12,819
93.395	AIDS MALIGNANCY CLINICAL TRIALS (AMC)	1568 G NA643 - 3	2012-09-01	2013-08-31	21,848
93.395	AIDS MALIGNANCY CLINICAL TRIALS (AMC)	PO 1568 G NA643	2013-09-01	2014-08-31	90,973
93.393	THE GEORGE WASHINGTON UNIVERSITY EAST COAST AIDS AND CANCER SPECIMEN RESOURCE	13-M110R	2013-09-23	2014-08-31	7,548
93.395	EAST COAST AIDS AND CANCER SPECIMEN RESOURCE	13-M1476	2012-09-01	2014-08-31	29,079
93.395	THE EAST COAST AIDS AND CANCER SPECIMEN RESOURCE (SUPPLEMENT)	12-M79R	2012-09-01	2015-08-31	387,217
N/A	THE MITRE CORPORATION MOLECULAR AND CELLULAR TECHNOLOGIES AND IMPLICATIONS	100996	2013-11-03	2014-11-02	64,203
N/A	MOLECULAR AND CELLULAR TECHNOLOGIES AND IMPLICATIONS	91687	2011-11-03	2013-11-02	120,796
93.394	THE REGENTS OF MICHIGAN SOUTHWEST ONCOLOGY GROUP BIOREPOSITORY	F032175	2012-09-01	2013-06-30	23,955
93.395	CANCER CONTROL AND PREVENTION BIostatISTICS CORE	F0032195	2012-06-01	2013-05-31	627
93.395	PCPT-SELECT COMBINED ACTIVITIES AT SWOG STATISTICAL CENTER	F0032195	2012-06-01	2013-05-31	(571)
93.395	SWOG CLINICAL COMMUNITY ONCOLOGY PROGRAM RESEARCH BASE	F0032201	2012-06-01	2013-05-31	(482)
93.701	SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT	F027026	2013-01-01	2013-06-30	—
93.855	THE SCRIPPS RESEARCH INSTITUTE CENTER FOR HIV/AIDS VACCINE IMMUNOLOGY AND IMMUNOGEN DISCOVERY (CHAVI-ID)	5-50272	2013-07-01	2014-06-30	52,506
N/A	THE UNIVERSITY OF TEXAS BLOOD BASED BIOMARKERS IN LUNG CANCER	00001594	2013-12-16	2014-09-24	59,496
N/A	VALIDATION OF BIOMARKERS FOR PROSTATE CANCER PROGNOSIS	00001915/PO 30003496	2014-04-09	2014-09-29	37,346
93.395	TARGETING ACT SIGNALING IN AML TRUSTEES OF INDIANA UNIVERSITY, INDIANA	AWOA	2012-09-01	2015-08-31	32,592
93.837	RACIAL/ETHNIC DIFFERENCES IN 25(OH)D AND PTH LEVELS AND CVD AMONG WOMEN	IN-4679710-FHCRC	2014-05-01	2015-04-30	3,986
N/A	RACIAL/ETHNIC DIFFERENCES IN 25(OH)D AND PTH LEVELS AND CVD AMONG WOMEN	AWOA	2013-12-01	2013-12-02	8,406
93.837	TUFTS UNIVERSITY CIRCULATING DIETARY AND METABOLIC FATTY ACIDS, MAJOR CVD OUTCOMES AND HEALTHY AGING	AWOA	2014-07-01	2015-06-30	95
93.395	UNIV OF MIAMI - MILLER SCHOOL MEDICINE CIRCULATING TUMOR CELL CAPTURE AND ANALYSIS IN MULTI-CENTER PROSTATE CANCER TRIAL	660215	2013-09-05	2014-08-31	17,097
93.855	UNIVERSITY OF ALABAMA THE BIOPHYSICAL UNDERPINNINGS OF GP 120 EVOLVABILITY	000338217-SP021-005	2013-06-01	2014-05-31	245,652
93.855	THE BIOPHYSICAL UNDERPINNINGS OF GP 120 EVOLVABILITY	000384599-014	2012-06-01	2013-05-31	342
93.393	UNIVERSITY OF ALASKA FAIRBANKS VALIDATING MULTIPLE STABLE ISOTOPE MEASURES OF DIET IN THE NPAAS FEEDING STUDY	UAF 14-0099/PO-FP427	2014-02-17	2015-01-31	2,741
93.226	UNIVERSITY OF ARIZONA PROSPECTIVE COMPARATIVE EFFECTIVENESS TRIAL FOR MALIGNANT BOWEL OBSTRUCTION	154141	2013-09-30	2014-09-29	57,564
93.866	BIOMARKERS AND GENETIC FACTORS RELATED TO SARCOPENIA IN OLDER WOMEN	Y482831	2007-09-15	2013-06-30	264
93.395	UNIVERSITY OF BRITISH COLUMBIA TRANSPLANTATION OF G-CSF STIMULATED MARROW VS BLOOD	08-2116	2008-07-01	2012-06-30	(1,869)
93.121	UNIVERSITY OF CALIFORNIA LOS ANGELES SALIVARY BIOMARKERS FOR SJORGREN'S SYNDROME DETECTION -DEFINITIVE CLINICAL VALIDATION	1350 G PC349	2013-05-01	2013-08-31	57,552
93.121	SALIVARY BIOMARKERS FOR SJORGREN'S SYNDROME DETECTION-DEFINITIVE VALIDATION	1350 G PC349	2013-09-01	2014-08-31	95,378
93.393	INCREASING HPV VACCINE UPTAKE IN A LOW INCOME ETHNIC MINORITY POPULATION	1916 G QA044	2012-05-01	2013-03-31	(5,084)
93.393	INCREASING HPV VACCINE UPTAKE IN A LOW INCOME ETHNIC MINORITY POPULATION	1917 G QA044	2013-04-01	2014-03-31	20,149
93.393	INCREASING HPV VACCINE UPTAKE IN A LOW INCOME ETHNIC MINORITY POPULATION	1918 G QA044	2014-04-01	2015-03-31	2,367
93.396	INFLUENCES OF MICROENVIRONMENT ON CANCER STEM CELLS	1490 G PB453	2013-09-01	2014-08-31	162,774
93.396	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO INFLUENCES OF THE MICROENVIRONMENT ON CANCER STEM CELLS	1490 G PB453	2012-09-01	2013-08-31	31,710
N/A	AN INTEGRATED COMPUTATIONAL PLATFORM FOR FLOW DATA ANALYSIS WITH INTEROPERABILITY BETWEEN DOMAIN EXPERTS	107991	2011-01-01	2014-04-30	46,572
N/A	PROTOCOL 1997 - HIGH-DOSE IMMUNOSUPPRESSION AND AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE SCLEROSIS (HALT MS) STUDY	ITN10118-00sc	2007-10-01	2014-04-30	222,518
12.420	PREDICTING PROSTATE CANCER PROGRESSION AT TIME OF DIAGNOSIS	6744SC	2011-06-15	2014-06-14	73,640
93.393	MODELING NEOPLASTIC PROGRESSION IN BARRETT'S ESOPHAGUS	6797SC	2011-06-01	2014-05-31	98,640
93.394	VALIDATION OF PROGNOSTIC AND PATHWAY SIGNATURES IN LETHAL PROSTATE CANCER	6961SC	2012-09-01	2013-08-31	8,456
93.855	PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM	7365SC	2012-09-01	2013-08-31	2,724
93.855	PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM	7365SC	2013-09-01	2014-08-31	27,927
93.855	VIRAL ONCOLOGY TRANSLATIONAL RESEARCH INITIATIVE SUPPLEMENT TO UCSF-GIVI CENTER FOR AIDS RESEARCH	7278SC	2012-09-01	2014-08-31	81,127
93.393	UNIVERSITY OF CHICAGO LIFESTYLE FACTORS AND LYMPHOMA: AN ASIA COHORT CONSORTIUM POOLING PROJECT	FP053223	2013-03-15	2015-02-28	54,082
93.393	UNIVERSITY OF HAWAII OBESITY, BODY FAT DISTRIBUTION AND CANCER RISK IN THE MULTIETHNIC COHORT	KA0100	2012-09-01	2013-08-31	238,442
93.393	OBESITY, BODY FAT DISTRIBUTION AND CANCER RISK IN THE MULTIETHNIC COHORT	KA0100	2013-09-01	2014-08-31	370,514
93.837	UNIVERSITY OF MARYLAND, BALTIMORE INCREASING STEM CELL NUMBERS WHILE RETAINING STEM CELL FUNCTION - NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM	SR00002708	2013-05-01	2014-10-31	321,103
93.837	INCREASING STEM CELL NUMBERS WHILE RETAINING STEM CELL FUNCTION-NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM	SR00002323	2012-08-01	2013-04-30	(310)
93.837	INDUCTION OF STEM CELL EXPANSION BY THE VASCULAR NICHE-ANCILLARY PROJECT	101330A/SR00003322	2014-05-01	2015-04-30	19,787
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM ADMINISTRATIVE COORDINATING CENTER	8363	2013-08-01	2014-04-30	6,998
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM ADMINISTRATIVE COORDINATING CENTER	8491	2013-08-01	2014-04-30	127,326

FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period- begin	Award period- end	Expenditures
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM PILOT STUDY	7421-SR00002589	2013-03-01	2013-03-02	\$ (44,324)
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM PILOT STUDY	SR00002589	2012-03-01	2014-06-30	188,161
93.394	UNIVERSITY OF MINNESOTA				
93.865	IMPACT OF GENETIC VARIATION ON RESPONSE TO GO THERAPY IN COG-AML CLINICAL TRIALS	P002603502	2012-04-05	2015-03-31	80,942
93.865	VIRAL IMMUNOMODULATION AND RATIONAL CMV VACCINE DESIGN	N001926102	2011-04-01	2015-01-31	77,981
93.113	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL				
93.113	EPIGENETIC MECHANISMS OF PM-MEDIATED CVD RISK	5-32973	2012-08-06	2015-04-30	20,895
93.855	GENETIC MODIFICATION OF PM-MEDIATED ARRHYTHMOGENESIS	5-30764	2010-08-01	2014-05-31	9,192
93.855	CAUSAL INFERENCE IN INFECTIOUS DISEASE PREVENTION STUDIES	5-30444	2009-12-01	2014-11-30	64,413
93.855	SYSTEMS IMMUNOGENETICS OF BIODEFENSE PATHOGENS IN THE COLLABORATIVE CROSS	5-33048	2012-08-05	2013-07-31	23,601
93.855	SYSTEMS IMMUNOGENETICS OF BIODEFENSE PATHOGENS IN THE COLLABORATIVE CROSS	5-33048	2013-08-01	2014-07-31	238,334
93.859	ROSETTA: AN INTEGRATED PROTEIN STRUCTURAL MODELING SUITE	5-30195	2009-09-01	2013-08-31	4,053
93.393	UNIVERSITY OF PENNSYLVANIA				
93.393	POST GWA STUDIES IN TESTICULAR GERM CELL TUMORS	560146	2012-09-21	2013-08-31	36,602
93.393	POST GWA STUDIES IN TESTICULAR GERM CELL TUMORS	561999	2013-09-18	2014-08-31	154,566
93.393	STATISTICAL METHODS FOR CANCER ABSOLUTE RISK PROTECTION	560862	2013-04-01	2014-03-31	26,443
93.396	STEM CELLS, DIFFERENTIATION AND THERAPEUTIC RESISTANCE IN AML	556407	2011-02-10	2015-01-31	258,963
93.398	STATISTICAL METHODS FOR THE DEVELOPMENT AND EVALUATION OF CANCER RISK PREDICTION	AWOA	2014-04-01	2015-03-31	14,441
93.398	UNIVERSITY OF PITTSBURGH				
N/A	PROPHYLAXIS VERSUS PREEMPTIVE THERAPY FOR CMV IN R-D+ LIVER TRANSPLANT RECIPIENTS	0024031-2	2011-09-26	2015-09-25	79,997
93.397	SPORE IN LUNG CANCER PROJECT 4: TARGETING NEUTROPHIL ELASTASE IN LUNG CANCER	9007675 (121211-1)	2012-09-01	2013-08-31	3,347
93.857	THE EMPHYSEMATOUS MICROENVIRONMENT PROMOTES LUNG TUMORIGENESIS AND PROGRESSION	0021343(121170-1)	2012-03-01	2015-04-30	39,523
93.855	THE ROLE OF NOVEL, UNCULTIVABLE BACTERIA IN INCIDENT PID	0022494(119409-1)	2011-08-05	2013-08-04	49,552
93.393	UNIVERSITY OF SOUTHERN CALIFORNIA				
93.393	FUNCTIONAL ANALYSIS OF GENOME WIDE ASSOCIATIONS IN COLORECTAL CANCER	H44554	2010-02-01	2015-01-31	10,037
93.393	IDENTIFYING OVARIAN CANCER SUSCEPTIBILITY ALLELES USING GENOME-WIDE SCAN DATA	H47764	2010-08-01	2013-07-31	8,987
93.393	TRANSDISCIPLINARY STUDIES OF GENETIC VARIATION FOR COLORECTAL CANCER	Y92562	2012-07-01	2013-06-30	1,014
93.393	TRANSDISCIPLINARY STUDIES OF GENETIC VARIATION FOR COLORECTAL CANCER	44614537	2013-07-01	2015-06-30	652,656
93.397	MULTI-SCALE COMPLEX SYSTEMS TRANSDISCIPLINARY ANALYSIS OF RESPONSE TO THERAPY	36469328	2013-03-01	2013-07-31	41,407
93.397	UNIVERSITY OF TEXAS HEALTH SCIENCES CENTE				
93.394	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM – ADMIN SUPPLEMENT	152907	2012-06-30	2013-06-29	237
93.394	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM: ADMIN SUPPLEMENT	155021	2013-06-30	2014-06-30	137,473
93.394	UNIVERSITY OF TEXAS M.D. ANTONIO				
93.394	BIOMARKERS AND CLINICAL PARAMETERS ASSOCIATED WITH GLEASON SCORE UPGRADING	156537	2013-07-01	2014-06-30	16,298
93.394	EDRN: CANARY PROSTATE ACTIVE SURVEILLANCE	153609	2012-12-01	2013-06-30	21
93.394	EDRN: DMCC CANARY PROSTATE SURVEILLANCE	155030	2013-07-01	2014-06-30	101,166
93.399	BIOLOGY OF THE PCPT: BIostatISTICS CORE	130636/130629	2009-05-01	2014-04-30	217,524
93.399	UNIVERSITY OF WASHINGTON				
N/A	AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM, AIDS-RELATED MALIGNANCIES	719482	2011-06-01	2012-05-31	(389)
N/A	DEFINING A NOVEL NON-TRANSCRIPTIONAL PAT	759321	2014-01-01	2014-12-31	2,702
N/A	GENETIC RISK FOR SMALLPOX VACCINE RELATED TO MYOCARDITIS	713535	2010-09-30	2014-09-29	126,581
12.420	TARGETING THE ABERRANT ANDROGEN RECEPTOR IN ADVANCED TREATMENT RESISTANT PROSTATE CANCER	757392	2013-09-30	2014-09-26	29,531
12.420	VACCINE TO PREVENT BREAST CANCER	731007	2011-09-30	2014-09-29	26,565
47.074	THE GENETIC ARCHITECTURE OF SOMATIC MUTATION RATE	757057	2013-07-01	2015-07-31	16,415
66.509	CENTER FOR CHILD ENVIRONMENTAL HEALTH RISKS – EPA FUNDS	710279	2010-10-01	2015-08-31	120,220
93.067	IMPACT OF CRYOTHERAPY VERSUS LOOP ELECTROSURGICAL EXCISION PROCEDURE (LEEP) ON HIV-1 CERVICAL SHEDDING	759227	2014-02-01	2014-07-31	28,819
93.113	CENTER FOR CHILD ENVIRONMENTAL HEALTH RESEARCH	754731	2013-08-01	2014-07-31	71,750
93.113	CENTER FOR CHILD ENVIRONMENTAL HEALTH RISKS RESEARCH	745341	2012-08-01	2013-07-31	5,216
93.113	ENDOTOXIN EXPOSURE AND RISK OF PARKINSONISM	664729	2009-09-01	2013-07-31	12,830
93.113	POLYCYCLIC AROMATIC HYDROCARBON EXPOSURE FROM URBAN AIR POLLUTION, HERPES VIRUS INFECTION AND IMMUNE FUNCTION IN UGANDAN CHILDREN	751574	2013-04-01	2014-03-31	13,175
93.135	ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW) – TALBOT SUBAWARD	745327	2012-09-30	2013-09-29	11,345
93.135	ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW) [TALBOT SUBAWARD]	755388	2013-09-30	2014-09-29	41,253
93.135	LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	745351	2012-09-30	2013-09-29	62,574
93.135	LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	755396	2013-09-30	2014-09-29	45,213
93.135	STAFF ASSIGNMENT: TAYLOR – ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW)	745325	2012-09-30	2013-09-29	10,371
93.172	A COMPREHENSIVE CATALOG OF DNASE I HYPERSENSITIVE SITES	746123	2012-09-21	2013-07-31	94,443
93.172	CLINICAL SEQUENCING IN CANCER: CLINICAL, ETHICAL, AND TECHNOLOGICAL STUDIES	755703	2013-08-01	2014-07-31	177,443
93.172	CLINICAL SEQUENCING IN CANCER: CLINICAL, ETHICAL, AND TECHNOLOGICAL STUDIES	756655	2013-12-01	2014-11-30	21,232
93.242	OPTIMIZING ANTIRETROVIRAL-BASED HIV PREVENTION FOR HIV AFRICAN DISCORDANT COUPLES	748628	2012-12-01	2013-11-30	7,412
93.286	INTRACELLULAR DELIVERY OF PROAPOPTOTIC PEPTIDE DRUGS	724156	2011-08-10	2015-05-31	28,074
93.286	NRI SMALL-ADVANCED BIOPHOTONICS FOR IMAGE-GUIDED ROBOTIC SURGERY	739117	2012-04-09	2015-03-31	90,702
93.350	ELUCIDATING MICRORNAS IN MYELOID DIFFERENTIATION IN LEUKEMIA	745215	2012-09-01	2015-08-31	15,899
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	743958	2012-06-01	2013-05-31	1,932
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES (KL2)	743751	2012-06-01	2013-05-31	(3,792)
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES (KL2)	755697	2013-06-01	2014-05-31	108,571
93.350	SUBAWARD FROM THE INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	AWOA	2014-06-01	2015-05-31	9,053
93.350	SUBAWARD: INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	754593	2013-06-01	2014-05-31	328,304
93.361	PALLIATIVE CARE SYMPTOM MANAGEMENT IN RURAL COMMUNITIES	AWOA	2014-06-01	2015-05-31	5,369
93.393	ACCURACY OF BREAST PATHOLOGY AND THE IMPACT OF TECHNOLOGY AND DOUBLE READING	728816	2011-09-12	2012-12-31	(1)
93.393	ACCURACY OF THE DIAGNOSIS OF MELANOMA AND THE IMPACT OF TECHNOLOGY AND DOUBLE READING	660067	2009-07-07	2014-05-31	83,203
93.393	DIGITAL PATHOLOGY: ACCURACY, VIEWING BEHAVIOR AND IMAGE CHARACTERIZATION	724565	2011-08-01	2015-05-31	147,214
93.393	GENTOXIC ESTROGEN RATIO: A NOVEL ESTROGEN BIOMARKER AND BREAST CANCER RISK	749763	2012-12-31	2014-11-30	92,719
93.393	HUMAN RECQ HELICASES IN BIOLOGY AND ONCOLOGY – PROJECT 5: HUMAN TUMOR ANALYSES	756621	2013-09-01	2015-07-31	29,255
93.393	HUMAN RECQ HELICASES IN BIOLOGY AND ONCOLOGY-PROJECT 5: HUMAN TUMOR ANALYSIS	742886	2012-07-01	2013-06-30	(255)
93.393	HUMAN RECQ HELICASES IN BIOLOGY AND ONCOLOGY-PROJECT 5: HUMAN TUMOR ANALYSIS	754062	2013-07-01	2014-06-30	32,135
93.393	MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY	756757	2013-07-01	2015-03-31	87,467
93.394	MR DIFFUSION TENSOR IMAGING FOR DETECTION AND CHARACTERIZATION OF BREAST LESIONS	700336	2010-07-16	2015-05-31	19,603
93.394	PANCREATIC JUICE BIOMARKER FOR PANCREATIC CANCER	726037	2011-08-01	2014-07-31	2,906
93.394	PHARMACOGENETICS IN CHILDREN WITH HIGH-RISK NEUROBLASTOMA	756819	2013-09-26	2015-08-31	55,724
93.394	ULTRASOUND ENHANCED DRUG PENETRATION FOR TREATMENT OF PANCREATIC CANCER	735227	2011-12-01	2014-08-31	48,374
93.395	ERYTHROPOIETIN BLOCKADE FOR THE TREATMENT OF CANCER	583994	2008-09-25	2013-07-31	3,454
93.395	MINIMALLY INVASIVE ABLATIVE THERAPIES IN PANCREATIC CYSTIC NEOPLASMS	753294	2013-07-01	2015-06-30	80,737
93.395	VIRAL ONCOPROTEIN TARGETED IMMUNE THERAPY FOR MERKEL CELL CARCINOMA	750685	2013-04-01	2015-03-31	274,316

FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award number	Award period begin	Award period- end	Expenditures
93.396	CORE A: MECHANISMS AND MARKERS OF PROSTATE CANCER METASTASES	753911	2013-08-01	2014-07-31	\$ 56,099
93.396	DETECTION, ISOLATION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS	745485	2012-08-01	2013-07-31	14,959
93.396	DETECTION, ISOLATION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS	753904	2013-08-01	2014-07-31	191,252
93.396	MECHANISMS AND MARKERS OF PROSTATE CANCER METASTASES	745494	2012-08-01	2013-07-31	2,412
93.396	PROJECT 2: TRANSMEMBRANE PROTEASES AND PROSTATE CARCINOGENESIS	745492	2012-08-01	2013-07-31	38,136
93.396	PROJECT 2: TRANSMEMBRANE PROTEASES AND PROSTATE CARCINOGENESIS	753907	2013-08-01	2015-07-31	270,585
93.398	BIOBHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	746437	2012-08-01	2013-07-31	3,210
93.398	BIOBHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	754909	2013-08-01	2014-07-31	31,313
93.398	CANCER PREVENTION TRAINING IN NUTRITION, EXERCISE AND GENETICS	754419	2013-07-01	2014-06-30	56,973
93.398	CANCER PREVENTION TRAINING-NUTRITION EXERCISE & GENETICS	743561	2012-07-01	2013-06-30	0
93.701	MEASURES OF ENDOCRINE SENSITIVITY IN EARLY BREAST CANCER	667640Z	2009-09-28	2013-08-31	26,662
93.837	CFAR: THE MOLECULAR PROFILING AND COMPUTATIONAL BIOLOGY CORE	AWOA	2014-06-01	2015-05-31	1,703
93.837	HEMATOLOGY K12 FELLOWSHIP	748840	2013-01-01	2013-05-31	(1,754)
93.837	HEMATOLOGY K12 FELLOWSHIP	752623	2013-06-01	2013-11-30	36,220
93.837	OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE	716038	2010-06-01	2013-05-31	(1,135)
93.837	STEM CELLS AND CARDIOVASCULAR REPAIR - PROJECT 3	741402	2012-06-01	2013-05-31	(6,700)
93.837	STEM CELLS AND CARDIOVASCULAR REPAIR - PROJECT 3	753008	2013-06-01	2014-05-31	271,780
93.838	STAFF ASSIGNMENT: BROWN - DATA COORDINATING FOR SYSTEMS BIOLOGY APPROACH TO THE MECHANISMS OF TB	745769	2012-09-01	2013-08-31	935
93.839	PROJECT 3 OF STEM CELL GENE THERAPY FOR HEMOGLOBINOPATHIES	AWOA	2014-04-01	2015-03-31	5,969
93.839	PROJECT 3 OF STEM CELL GENE THERAPY FOR HEMOGLOBINOPATHIES	751143	2013-04-01	2014-03-31	40,896
93.847	A TWIN STUDY OF OBESITY PATHOGENESIS USING FMRI	729556	2011-09-20	2015-08-31	37,284
93.847	CHROMATIN RESPONSE TO ACUTE RENAL INJURY	709940	2010-08-01	2014-07-31	205,290
93.847	CLINICAL AND MOLECULAR CHARACTERIZATION OF FAMILIAL MARROW FAILURE SYNDROMES	746003	2012-09-01	2013-08-31	13,521
93.847	DIABETES RESEARCH CENTER	751171	2013-05-01	2013-11-30	64,091
93.847	DIABETES RESEARCH CENTER	AWOA	2013-12-01	2014-11-30	102,930
93.847	DIETARY FUCTOSE AND INTESTINAL PERMEABILITY	736222	2011-12-01	2013-05-12	(9,721)
93.847	DIETARY FUCTOSE AND INTESTINAL PERMEABILITY	753568	2013-03-13	2013-11-30	16,401
93.847	DIETARY FUCTOSE AND INTESTINAL PERMEABILITY	AWOA	2013-12-01	2014-11-30	18,754
93.847	EXPLAINING THE SES/OVERWEIGHT AND OBESITY RELATIONSHIP	646880	2009-03-01	2014-02-28	44,355
93.847	FEASIBILITY, EFFICACY, AND MECHANISMS OF SURGICAL VS MEDICAL DIABETES TREATMENT	715230	2010-08-18	2014-06-30	12,191
93.847	HfMC PROSPECTIVE BIOPREPOSITORY	748869	2012-06-01	2014-05-31	8,393
93.847	INTESTINAL MICROBIOTA IN DIVERTICULAR DISEASE	701877	2010-07-26	2015-06-30	101,008
93.847	Y AND CHRE AND LOW-GRADE ADIPOSE TISSUE INFLAMMATION	742963	2012-07-01	2013-06-30	14,790
93.853	DRUG DISCOVERY FOR THE PREVENTION OF HEARING LOSS	742840	2012-07-01	2013-06-30	(197)
93.853	DRUG DISCOVERY FOR THE PREVENTION OF HEARING LOSS	753179	2013-07-01	2015-06-30	31,451
93.853	JOUBERT SYNDROME AND RELATED DISORDERS OF HINDBRAIN DEVELOPMENT	745169	2012-09-01	2014-06-30	2,852
93.853	PROJECT 2: MUSCLE CELL TRANSPLANTATION IN CANINE DMD	750389	2013-04-01	2014-03-31	166,398
93.855	C CELL RESPONSES AT THE FORESKIN	745363	2012-06-01	2013-05-31	(1)
93.855	B CELL RESPONSES AT THE FORESKIN	756723	2013-06-01	2014-05-31	31,966
93.855	CENTER FOR AIDS RESEARCH (CFAR) BIOMETRICS CORE	752299	2013-06-01	2014-05-31	78,785
93.855	CENTER FOR AIDS RESEARCH (CFAR) BIOMETRICS CORE	AWOA	2014-06-01	2015-05-31	4,092
93.855	CENTER FOR AIDS RESEARCH (CFAR): CORE 1- IMMUNOLOGY CORE	AWOA	2014-06-01	2015-05-31	1,844
93.855	CFAR ADMINISTRATIVE CORE - CO-DIRECTOR	752301	2013-06-01	2014-05-31	32,505
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES CORE	752300	2013-06-01	2014-05-31	329,215
93.855	CFAR: BLOCKING INFLAMMATION IN HIV CO-INFECTION	754957	2013-08-15	2015-08-15	14,310
93.855	CFAR: THE MOLECULAR PROFILING AND COMPUTATIONAL BIOLOGY CORE	752629	2013-06-01	2014-05-31	255,338
93.855	CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	755563	2013-07-01	2014-06-30	73,427
93.855	CONSERVED ELEMENTS THERAPEUTIC DNA VACCINE FOR HIV	756393	2013-08-15	2014-07-31	7,866
93.855	CURATIVE THERAPIES FOR HIV SCIENTIFIC WORKING GROUP	755154	2013-06-01	2014-05-31	19,178
93.855	DESIGN AND FUNCTION OF FLAGELLIN-BASED IMMUNOGENS FOR BROADLY NEUTRALIZING IMMUNITY TO HIV	672286	2009-09-04	2015-02-28	127,537
93.855	EVALUATING THE EFFECT OF PERIODIC PRESUMPTIVE TREATMENT FOR VAGINAL INFECTIONS ON THE VAGINAL MICROBIOTA: A DETAILED MOLECULAR ANALYSIS OF SAMPLES FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL	736792	2012-02-06	2015-01-31	339,622
93.855	EVOLUTION AND EMERGENCE OF SIMIAN RETROVIRUSES IN SOUTH ASIA	572286	2008-08-01	2014-02-28	49,026
93.855	IMMUNE MECHANISMS OF FLAVIVIRUS CONTROL: PROJECT 5	738704	2012-05-01	2013-04-30	4
93.855	IMMUNE MECHANISMS OF FLAVIVIRUS CONTROL: PROJECT 6	751480	2013-05-01	2014-04-30	185,657
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	749466	2012-07-01	2013-06-30	(926)
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	749725	2012-07-01	2013-06-30	2,337
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	756159	2013-07-01	2014-06-30	70,393
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	756918	2013-07-01	2014-06-30	61,300
93.855	INFRASTRUCTURE AWARD - UGANDA CANCER INSTITUTE	753228	2013-06-01	2013-12-31	1,335
93.855	INTENSE VALIDATION OF A MATHEMATICAL MODEL OF HERPES SIM	714348	2011-03-01	2015-02-28	104,090
93.855	INTERACTION BETWEEN HSV-2 AND THE VAGINAL MICROBIOME IN THE FEMALE GENITAL TRACT	746989	2012-08-01	2014-07-31	242,543
93.855	MACHINE LEARNING TO EXPAND OUR KNOWLEDGE OF APOBEC3 SPECIFICITY AND IMPROVE CLASIFICATION OF HIV MUTATIONS	757800	2013-11-20	2014-05-31	26,843
93.855	MALE URETHRITIS: NOVEL ETIOLOGIES AND NATURAL HISTORY - (MPI)	759048	2014-04-01	2015-03-31	4,823
93.855	MECHANISMS OF CD8+ T CELL IMMUNE SURVEILLANCE IN HUMAN GENITAL SKIN AND MUCOSA AFTER HSV REACTIVATION	744456	2012-08-01	2013-07-31	33,057
93.855	NANOPARTICLE MICROBICIDES FOR DELIVERY OF COMBINATION ANTIRETROVIRAL DRUGS	754715	2013-07-01	2014-06-30	89,059
93.855	PREP AND PROTECTIVE IMMUNE RESPONSE AGAINST HIV-1	737619	2012-04-01	2015-03-31	366,182
93.855	PREP AND PROTECTIVE IMMUNE RESPONSE AGAINST HIV-2	AWOA	2013-04-01	2013-04-02	(43,682)
93.855	PREP AND PROTECTIVE IMMUNE RESPONSES AGAINST HIV-1	737618	2012-04-01	2015-03-31	19,917
93.855	SEVERE CHRONIC NEUTROPENIA INTERNATIONAL REGISTRY	705277	2010-09-01	2014-08-31	30,440
93.855	STATISTICAL ISSUES IN AIDS RESEARCH	638936	2009-05-01	2014-04-30	114,941
93.855	STATISTICAL ISSUES IN AIDS RESEARCH	759393	2014-05-01	2015-04-30	10,448
93.855	THE ACQUISITION OF BACTERIAL VAGINOSIS IN LESBIANS	703785	2010-09-15	2013-08-31	61,685
93.855	THE ROLE OF NOVEL BACTERIA IN MALE URETHRITIS	724851	2011-07-25	2014-06-30	162,110
93.855	UNIVERSITY OF WASHINGTON CENTER FOR AIDS RESEARCH	752537	2013-06-01	2014-05-31	82,563
93.859	UW POST-BACCALAUREATE RESEARCH EDUCATION PROGRAM (PREP)	733206	2012-02-01	2015-01-31	14,212
93.859	UW POST-BACCALAUREATE RESEARCH EDUCATION PROGRAM (PREP)	AWOA	2014-02-01	2014-02-02	-
93.865	MALE CONTRACEPTION RESEARCH CENTER GRANT: PROJECT IV	747844	2012-09-17	2013-06-30	3,106
93.865	MALE CONTRACEPTION RESEARCH CENTER GRANT: PROJECT IV	755343	2013-07-01	2014-06-30	22,224
93.865	ORGANIZATION AND FUNCTION OF TRANSCRIPTION-CONTROL ELEMENTS AT THE HUMAN FRAGILE-X LOCUS	744263	2012-07-01	2013-06-30	(48)
93.865	REGULATION OF THE FANCONI ANEMIA PATHWAY BY PHOSPHATASES	745289	2012-09-01	2013-11-30	72,273
93.866	DEFINING THE IMPACT OF MITOCHONDRIAL MEMBRANE COMPOSITION AND MAINTENANCE ON AGING	753906	2013-07-15	2014-06-30	29,300
93.866	DOSE-RESPONSE RELATIONSHIPS BETWEEN CIRCULATING AND INTRAPROSTATIC ANDROGENS IN MEN	721448	2011-07-01	2015-06-30	51,117
93.989	AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM, AIDS-RELATED MALIGNANCIES RESEARCH TRAINING	743714	2012-06-01	2014-05-31	868

FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2014

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.989	FOGARTY GLOBAL HEALTH FELLOWSHIP	752408	2013-09-01	2015-06-30	\$ 9,911
93.989	FOGARTY GLOBAL HEALTH FELLOWSHIP - UPCID	750139	2013-03-01	2015-06-30	2,375
N/A	CFAR ADMINISTRATIVE CORE - CO DIRECTOR	AWOA	2014-06-01	2015-05-31	1,690
N/A	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES	AWOA	2014-06-01	2015-05-31	24,314
93.867	UNIVERSITY OF WISCONSIN DIET AND LIFESTYLE FACTORS REDUCING RISK FOR AGE-RELATED EYE DISEASE	277K314	2010-12-01	2013-11-30	5,125
93.394	VAN ANDEL RESEARCH INSTITUTE TARGETED GLYCOMICS AND AFFINITY REAGENTS FOR CANCER BIOMARKER DEVELOPMENT	BH-10-40234-01	2013-07-01	2014-06-30	19,950
93.396	ROLE OF ALPHA6 BETA1 INTEGRIN IN PROSTATE CANCER VANDERBILT UNIVERSITY MEDICAL CENTER	FHCRC-NIH-CM-10-4022	2012-05-01	2013-09-30	4,970
93.393	CANCER MORTALITY AMONG MILITARY PARTICIPANTS AT US NUCLEAR WEAPONS TESTS	VUMC 37160	2013-07-01	2014-06-30	28,145
93.393	CANCER MORTALITY AMONG MILITARY PERSONNEL AT U.S. NUCLEAR WEAPONS TESTS	VUMC 37160	2012-07-01	2013-06-30	5,440
93.393	MODIFIABLE RISK FACTORS FOR FATAL PROSTATE CANCER: A PROSPECTIVE STUDY IN ASIA WAKE FOREST UNIVERSITY HEALTH SCIENCES	VUMC 39615	2013-04-01	2014-03-31	39,886
N/A	VALIDATING THE CHRONIC CONDITION OF WAREHOUSE (CCW) ALZHEIMER'S DISEASE AND RELATED DISORDERS OF SENILE DEMENTIA IDENTIFICATION ALGORITHM IN WHI-LINKED CMS DATA	2013028381	2013-03-01	2013-09-30	8,208
93.393	GENE-HORMONE THERAPY INTERACTION AND THE RISK OF BREAST CANCER	10633	2011-03-01	2015-02-28	6,045
93.393	GENETIC PROFILING IN PCPT: PROSTATE CANCER RISK, PSA, LEVEL AND CHEMOPREVENTION WESTAT	10342	2011-07-01	2013-06-30	(3,096)
N/A	CANCER IMMUNOTHERAPY TRIAL NETWORK (CITN)	8339-S07	2012-08-31	2013-08-30	46,519
	Grand Total -Pass Through Funds				\$ <u>29,347,888</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

**(1) Basis of Presentation**

The accompanying schedule of expenditures of federal awards (SEFA) includes the federal grant activity of Fred Hutchinson Cancer Research Center and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the financial statements.

**(2) Subrecipients**

Of the federal expenditures presented in the Schedule of Federal Expenditures of Federal Awards, Fred Hutchinson Cancer Research Center provided federal awards to subrecipients as follows:

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
A COHORT STUDY OF SESSILE SERRATED POLYPS AND SUBSEQUENT COLORECTAL NEOPLASIA	93.393	\$ 160,360
A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMONG AMERICAN INDIANS	93.393	2,873
A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMONG AMERICAN INDIANS	93.393	68,093
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	3,906
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	5,530
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	9,930
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	124,729
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	17,934
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	87,920
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	1,003
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	29,701
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	16,701
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	35,839
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	33,289

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	\$ 91,958
ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	93.393	8,599
ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	93.393	3,529
ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	93.393	172,333
ACQUISITION AND LOSS OF NEISSERIA MENINGITIDIS CARRIAGE IN HOUSEHOLDS IN MALI	93.855	19,236
ADIPOSE TISSUE INFLAMMATION AND ESTROGEN SYNTHESIS	93.393	3,513
ADVANCED DEVELOPMENT OF IMMUNO-MRM TECHNOLOGY TO ANALYZE ARCHIVED CANCER TISSUES	93.394	6,707
ADVANCED DEVELOPMENT OF IMMUNO-MRM TECHNOLOGY TO ANALYZE ARCHIVED CANCER TISSUES	93.394	11,677
AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	93.394	230
AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	93.394	2,848
AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	93.394	19,878
AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	93.394	2,941
AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	93.394	3,909
AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	93.394	1,849
AIDS MALIGNANCY CLINICAL TRIALS (AMC)	93.395	7,249
AIDS MALIGNANCY CLINICAL TRIALS (AMC)	93.395	100

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
ALPHA RADIOIMMUNOTHERAPY FOR LYMPHOMA TREATMENT	93.395	\$ 68,110
ALPHA RADIOIMMUNOTHERAPY FOR LYMPHOMA TREATMENT	93.395	20,559
ALPHA RADIOIMMUNOTHERAPY FOR LYMPHOMA TREATMENT	93.395	10,114
AN ALGORITHM FOR CONTROL OF BIOLOGICAL TIME	12.910	18,802
AN ALGORITHM FOR CONTROL OF BIOLOGICAL TIME	12.910	11,963
AN INTEGRATED COMPUTATIONAL AND FUNCTIONAL GENOMICS DISCOVERY ENGINE FOR PRE-CLINICALLY VALIDATED CANCER DRUG TARGETS	93.394	206,917
ANALYZING HETEROGENEITY OF ONCOGENIC PATHWAY ACTIVATION IN OVARIAN CANCER USING A NOVEL, HIGH-THROUGHPUT	12.420	20,781
BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	93.393	16,512
BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	93.393	2,783
BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	93.393	1,741
BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	93.393	9,341
BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	93.393	34,477
BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	93.393	37,436
BIGDATA: MID-SCALE: DA: ESCE: COLLABORATIVE RESEARCH: SCALABLE STATISTICAL COMPUTING FOR EMERGING OMICS DATA STREAMS	47.070	83,178
BIGDATA: MID-SCALE: DA: ESCE: COLLABORATIVE RESEARCH: SCALABLE STATISTICAL COMPUTING FOR EMERGING OMICS DATA STREAMS	47.070	26,067
BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	93.172	5,378
BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	93.172	140,497
BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	93.172	85,388



**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	93.172	\$ 17,942
BIOLOGY AND PROGNOSTIC IMPLICATIONS OF FLT3 MUTATIONS IN AML	93.394	4,770
BIOLOGY AND PROGNOSTIC IMPLICATIONS OF FLT3 MUTATIONS IN AML	93.394	27,134
BIOMARKER DISCOVERY FOR MITOCHONDRIAL TOXICANTS USING METABOLIC FOOTPRINTING	93.113	50,539
BIOMARKER DISCOVERY FOR MITOCHONDRIAL TOXICANTS USING METABOLIC FOOTPRINTING	93.113	110,209
BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT	93.395	7,622
BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT	93.395	56,479
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	12,238
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	31,685
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	1,400
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	3,688
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	1,028
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	23,540
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	40,287
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	47,570
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	10,036
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	27,532
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	114,292
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	51,258
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	68,790
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	28,714
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	137
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	107,932
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	12,961
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	74,325
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	93,464
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	16,899
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	10,544

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	\$ 47,914
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	158,149
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	48,871
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	1,775
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	36,210
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	690
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	36,034
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	83,727
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	2,710
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	50,790
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	54,401
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	57,172
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	29,722
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	78,803
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	18,850
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	49,331
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	77,243
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	21,906
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	2,846
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	19,555
CANCER IMMUNOTHERAPY TRIAL NETWORK (CITN)	0.00	40,219
CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	93.395	297,278
CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	93.395	7,000
CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	93.395	56,000
CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	93.395	651,426
CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA	93.395	422
CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA	93.395	64,206
CD45 PRETARGETED RADIOIMMUNOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML)	93.395	89,641
CD8+ CELL IMMUNITY TO CYTOMEGALOVIRUS	93.395	33,005
CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER GENOMICS-CANCERGEN	93.701	8,822
CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER GENOMICS-CANCERGEN	93.701	5,631

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER GENOMICS-CANCERGEN	93.701	\$ 19,259
CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER GENOMICS-CANCERGEN	93.701	21,636
CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DISPARITIES	93.397	16,752
CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DISPARITIES	93.397	165
CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DISPARITIES	93.397	296
CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DISPARITIES	93.397	27,332
CHARACTERIZATION OF (HIV)-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMEN	93.855	72,899
CHARACTERIZATION OF (HIV)-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMEN	93.855	7,566
CHARACTERIZATION OF (HIV)-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMEN	93.855	101,187
CHARACTERIZATION OF (HIV)-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMEN	93.855	4,076
CHEMOPROTECTION AGAINST AMINOGLYCOSIDE- INDUCED OTOTOXICITY	93.173	48,919
CHEMOPROTECTION AGAINST AMINOGLYCOSIDE- INDUCED OTOTOXICITY	93.173	89,134
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	5,022
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	323,587
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	90,022
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	314,343
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	8,808
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	80
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	9,595
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	74,157

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	\$ 206,249
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	706,987
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	3,958
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	183,186
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	288,128
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	1,983
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	9
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	104,208
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	459,905
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	40,874
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	21,997
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	18
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	64,626
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	51,918
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	9,756
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	13,513
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	10,967
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	54,929
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	61,171
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	45,162

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	93.855	\$ 17,011
COLLABORATION FOR A HEALTHY COMMUNITY	93.307	22,107
COLLABORATION FOR A HEALTHY COMMUNITY	93.307	11,722
COLLABORATION FOR A HEALTHY COMMUNITY	93.307	11,183
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	(14)
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	24,551
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	12,044
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	120,430
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	119,439
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	34,864
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	33,429
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	16,676
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	31,361
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	41,806
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	42,464
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	33,769
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	9,581
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	124,222
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	244,744
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	15,058
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	16,930

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	\$ 10,143
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	15,980
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	88,905
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	19,829
CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO PLATELETS	93.837	11,625
CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO PLATELETS	93.837	102,056
CORE CENTER OF EXCELLENCE IN HEMATOLOGY	93.849	250
CORE CENTER OF EXCELLENCE IN HEMATOLOGY	93.847	296
CORE CENTER OF EXCELLENCE IN HEMATOLOGY	93.847	9,097
CROSS -SPECIES NETWORK APPROACH TO PREDICT EPISTATIC CANCER SUSCEPTIBILITY GENES	93.396	10,392
CYTOTOXIC T-CELL REPOSSES TO HSV IN HIV- INFECTED PERSONS	93.855	208,220
CYTOTOXIC T-CELL REPOSSES TO HSV IN HIV- INFECTED PERSONS	93.855	30,687
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	14,380
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	74,850
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	2,412,085
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	14,100
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	57,623
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	31,111
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	31,528

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	\$ 9,728
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	95,245
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	43,687
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	17,754
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	74,149
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	53,954
DEVELOPING UBIQUITIN LIGASE AGONISTS AS CANCER THERAPEUTICS	93.395	112,802
DEVELOPMENT OF A COMPREHENSIVE MODEL FOR COLORECTAL CANCER RISK PREDICTION	93.393	89,616
DEVELOPMENT OF A COMPREHENSIVE MODEL FOR COLORECTAL CANCER RISK PREDICTION	93.393	68,000
DEVELOPMENT OF A COMPREHENSIVE MODEL FOR COLORECTAL CANCER RISK PREDICTION	93.393	11,128
DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES IN THE MACAQUE SHIV MODEL	93.855	75,530
DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES FOR HEMOGLOBINOPATHIES	93.839	126,751
DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES FOR HEMOGLOBINOPATHIES	93.839	65,000
DIETARY FRUCTOSE AND LOW-GRADE INFLAMMATION	93.837	9,293
DISCOVERY AND OPTIMIZATION OF AML PROGNOSTIC BIOMARKERS	93.394	13,792
DISCOVERY AND OPTIMIZATION OF AML PROGNOSTIC BIOMARKERS	93.394	15,049
DYNAMICS OF GRADIENT SENSING IN SINGLE CELLS	93.859	73,601

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	\$ 4,421
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	55,238
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	139,602
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	13,728
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	18,818
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	26,750
EARLY DETECTION RESEARCH NETWORK: DATA MANAGEMENT AND COORDINATING CENTER	93.394	84,440
ENGRAFTMENT AND INVIVO SELECTION OF HIV- PROTECTED STEM CELLS	93.839	19
ENGRAFTMENT AND INVIVO SELECTION OF HIV- PROTECTED STEM CELLS	93.839	2,292
ENGRAFTMENT AND INVIVO SELECTION OF HIV- PROTECTED STEM CELLS	93.839	19,295
EPIDEMIOLOGIC FACTORS AND SURVIVAL BY MOLECULAR SUBTYPES OF OVARIAN CANCER	93.393	25,519
EPIDEMIOLOGIC FACTORS AND SURVIVAL BY MOLECULAR SUBTYPES OF OVARIAN CANCER	93.393	20,753
EPIDEMIOLOGIC FACTORS AND SURVIVAL BY MOLECULAR SUBTYPES OF OVARIAN CANCER	93.393	14,582
EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS IN THE WOMEN'S HEALTH INITIATIVE	93.172	52,656
EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	93.113	24,181
EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	93.113	16,659
EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	93.113	138,495
ESOPHAGEAL CANCER FROM CELLS TO POPULATION: A MULTISCALE APPROACH	93.393	1,842
ESOPHAGEAL CANCER FROM CELLS TO POPULATION: A MULTISCALE APPROACH	93.393	86,926
ESOPHAGEAL CANCER FROM CELLS TO POPULATION: A MULTISCALE APPROACH	93.393	43,153
EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	93.393	1,639
EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	93.393	4,441
EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	93.393	27,000



**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
EVALUATION OF PLURIPOTENT STEM CELL-DERIVED BLOOD CELLS IN NONHUMAN PRIMATE MODEL	93.839	\$ 14,086
EVALUATION OF PLURIPOTENT STEM CELL-DERIVED BLOOD CELLS IN NONHUMAN PRIMATE MODEL	93.839	56,400
EVOLUTION OF CANCER-SPECIFIC MOLECULAR REQUIREMENTS FOR GLIOBLASTOMA MULTIFORME (PQ8)	93.396	10,525
EVOLUTION OF CANCER-SPECIFIC MOLECULAR REQUIREMENTS FOR GLIOBLASTOMA MULTIFORME (PQ8)	93.396	30,170
EXONIC VARIANTS AND THEIR RELATION TO COMPLEX TRAITS IN MINORITIES OF THE WHI	93.172	13,355
EXONIC VARIANTS AND THEIR RELATION TO COMPLEX TRAITS IN MINORITIES OF THE WHI	93.172	21,136
EXPANSION OF CARDIAC AND HEMATOPOIETIC PROGENITORS BY WNT AND NOTCH (MPI)	93.837	179,814
EXPANSION OF CARDIAC AND HEMATOPOIETIC PROGENITORS BY WNT AND NOTCH (MPI)	93.837	136,520
EXPANSION OF CARDIAC AND HEMATOPOIETIC PROGENITORS BY WNT AND NOTCH (MPI)	93.837	97,980
EXPANSION OF CARDIAC AND HEMATOPOIETIC PROGENITORS BY WNT AND NOTCH (MPI)	93.837	44,382
FOAMY VIRUS ZOO NOTIC TRANSMISSION FROM NEW WORLD MONKEYS	93.855	27,492
FUNCTIONAL METHODS FOR RADIATION EXPOSURE AND BIOMARKER DATA	93.113	21,542
GENE THERAPY FOR FANCONI ANEMIA	93.839	9,641
GENETIC MECHANISMS OF SURVIVORSHIP DISPARITIES AFTER UNRELATED HCT	93.393	7,739
GENETIC MECHANISMS OF SURVIVORSHIP DISPARITIES AFTER UNRELATED HCT	93.393	302
GENETIC PROGRESSION OF PANCREATIC MUCINOUS CYSTIC NEOPLASMS TO INVASIVE CARCINOMA	93.396	5,756
GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN COLON CANCER	93.393	(529)
GUT MICROBIOTA AND COLONIC GENE EXPRESSION: A LIGRAN TRIAL IN HUMANS	93.393	95,341
GUT MICROBIOTA AND COLONIC GENE EXPRESSION: A LIGRAN TRIAL IN HUMANS	93.393	77,918

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES IN THE WHI	93.172	\$ 4,532
GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES IN THE WHI	93.172	35,753
HEMATOPOIETIC CHEMOPROTECTION IN GLIOBLASTOMA PATIENTS	93.395	8,059
HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	93.855	13,857
HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	93.855	361,498
HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	93.855	26,886
HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	93.855	92,812
HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	93.855	72,825
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	32,828
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	(30,645)
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	(1,029)
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	(32,828)
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	30,645
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	738,319
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	172,546
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	37,864

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	\$ 176,903
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	16,955
HPV CAPSID ANTIBODIES	93.855	28,202
HPV CAPSID ANTIBODIES	93.855	4,511
HUMAN IMMUNOLOGY PROJECT CONSORTIUM DATABASE HIPC-DB_RESEARCH PORTAL	0.00	10,788
HVTN LABORATORY PROGRAM	93.855	4,632
HVTN LABORATORY PROGRAM	93.855	(4,633)
HVTN LABORATORY PROGRAM	93.855	1,680
HVTN LABORATORY PROGRAM	93.855	187,619
HVTN LABORATORY PROGRAM	93.855	12,232
HVTN LABORATORY PROGRAM	93.855	7,888
HVTN LABORATORY PROGRAM	93.855	569,784
HVTN LABORATORY PROGRAM	93.855	44,803
HVTN LABORATORY PROGRAM	93.855	31,905
HVTN LABORATORY PROGRAM	93.855	84,935
HVTN LABORATORY PROGRAM	93.855	1,623
HVTN LABORATORY PROGRAM	93.855	(14,963)
HVTN LABORATORY PROGRAM	93.855	58,115
HVTN LABORATORY PROGRAM	93.855	127,717
HVTN LABORATORY PROGRAM	93.855	128,460
HVTN LABORATORY PROGRAM	93.855	17,187
HVTN LABORATORY PROGRAM	93.855	725,384
HVTN LABORATORY PROGRAM	93.855	388,044
HVTN LABORATORY PROGRAM	93.855	528,748
HVTN LABORATORY PROGRAM	93.855	26,277
HVTN LABORATORY PROGRAM	93.855	240,902
HVTN LABORATORY PROGRAM	93.855	39,915
HVTN LABORATORY PROGRAM	93.855	30,357
HVTN LABORATORY PROGRAM	93.855	20,345
HVTN LABORATORY PROGRAM	93.855	52,894
HVTN LABORATORY PROGRAM	93.855	42,021
HVTN LABORATORY PROGRAM	93.855	34,316
HVTN LABORATORY PROGRAM	93.855	32,984
HVTN LABORATORY PROGRAM	93.855	47,938
HVTN LABORATORY PROGRAM	93.855	69,031

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
HVTN LABORATORY PROGRAM	93.855	\$ 38
HVTN LABORATORY PROGRAM	93.855	6,900
HVTN LABORATORY PROGRAM	93.855	24,636
HVTN LABORATORY PROGRAM	93.855	36,319
HVTN LABORATORY PROGRAM	93.855	32,426
HVTN LABORATORY PROGRAM	93.855	208,754
HVTN LABORATORY PROGRAM	93.855	412,457
HVTN LABORATORY PROGRAM	93.855	697,595
HVTN LABORATORY PROGRAM	93.855	364,578
HVTN LABORATORY PROGRAM	93.855	45,021
HVTN LABORATORY PROGRAM	93.855	34,964
HVTN LABORATORY PROGRAM	93.855	14,724
HVTN LABORATORY PROGRAM	93.855	37,395
HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS	93.855	4,633
HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS	93.855	38,867
HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS	93.855	147,154
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	3,849
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	10,082
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	4,133
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	7,542
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	4,374
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	1,819
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	1,186
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	19,494
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	17,898
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	8,291
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	160,834

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	\$ 2,857
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	18,501
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	7,093
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	81,595
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	81,505
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	5,272
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	971,567
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	169,082
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	37,204
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	33,257
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	94,919
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	37,447
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	27,615
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	19,758
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	142,613
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	7,697
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	565,613
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	190,308
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	310,385
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	198,130

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	\$ 281
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	99,783
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	173,879
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	286,575
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	419,830
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	489,200
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	360,872
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	741,421
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	297,611
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	583,416
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	259,940
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	71,244
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	23,050
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	100,550
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	171,993
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	536,835
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	249,631
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	305,949
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	134,136
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	154,946

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	\$ 291,801
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	95,253
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	104,434
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	12,777
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	47,248
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	370,486
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	66,190
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	266,018
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	84,495
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	501,291
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	150,590
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	492,506
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	13,017
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	1,666
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	18,685
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	85,828
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	58,425
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	23,050
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	184,431
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	39,878
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	197,122

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	\$ 9,254
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	180,293
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	49,996
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	974
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	17,384
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	4,493
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	35,060
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	21,842
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	10
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	14,217
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	61,807
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	54,458
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	14,395
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	53,031
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	19,916
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	38,875
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	12,837
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	4,908
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	32,955
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	52,411
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	135,970



**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	\$ 34,669
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	3,602
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	1,122,064
HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	93.855	94,608
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	93.394	13,334
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	93.394	587
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	93.394	161,114
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	93.394	24,474
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	93.394	72,969
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM: ADMIN SUPPLEMENT	93.394	34,895
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(9,335)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(2,607)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	15,632
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(878)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(4,027)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	5,903
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,260

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	\$ 7,039
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	8,881
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,027
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	1,042
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	6,894
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	15,827
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	10,781
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	10,873
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	15,632
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(15,632)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	878
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	12,754
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	3,960
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,415
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	8,417
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	438
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,661
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	195
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(17,545)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	13,645

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	\$ 1,120
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	3,289
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,971
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	5,242
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	12,622
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	52,418
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	14,283
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	22,636
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	13,645
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(13,645)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,277
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,661
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	195
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	46,229
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	45,633
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	9,152
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	6,464
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	61,191
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(6,008)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	(7,972)

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	\$ (878)
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	3,289
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,381
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,682
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	18,276
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	21,700
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	1,621
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	9,683
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	6,666
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	17,167
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	878
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	10,043
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	10,112
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	1,836
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	3,782
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	1,548
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,661
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	195
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,700
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	8,910

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	\$ 203
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	7,972
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,758
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	17,361
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	29,842
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	46,270
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,602
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	21,421
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	8,910
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,607
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	11,340
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,800
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	7,788
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	127,243
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	268
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	21,706
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	28,120
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	8,190
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	14,833
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,795

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	\$ 2,960
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	562
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	6,494
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	10,306
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,027
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	5,028
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	6,040
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	62,449
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	1,824
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	9,773
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,075
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	11,458
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	391
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	450
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	5,709
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	253
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	2,093
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	4,300
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	205
IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND GENITAL MUCOSAL IMMUNITY	93.121	449

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND GENITAL MUCOSAL IMMUNITY	93.121	\$ 12,141
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	13,839
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	3,320
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	9,289
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	11,830
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	5,300
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	7,612
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	5,928
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	7,682
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	8,183
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	31,134
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	39,353
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	3,713
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	5,333
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	504
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	43,297
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	41,025

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	\$ 37,706
INTERGRATED SENSOR TECHNOLOGY FOR REAL- TIME RECORDING OF FOOD INTAKE	93.393	63,274
INTERGRATED SENSOR TECHNOLOGY FOR REAL- TIME RECORDING OF FOOD INTAKE	93.393	16,247
INTERGRATED SENSOR TECHNOLOGY FOR REAL- TIME RECORDING OF FOOD INTAKE	93.393	70,164
INTERNET STUDIES TO ENHANCE LONG TERM SURVIVORSHIP AFTER HEMATOLOGIC MALIGNANCY	93.395	18,780
INTERNET STUDIES TO ENHANCE LONG TERM SURVIVORSHIP AFTER HEMATOLOGIC MALIGNANCY	93.395	30,316
LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND OFFSPRING	93.393	29,474
LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND OFFSPRING	93.393	13,107
LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND OFFSPRING	93.393	13,156
LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND OFFSPRING	93.393	6,567
LC: HIV VACCINE TRIALS NETWORK	93.855	275,668
LC: HIV VACCINE TRIALS NETWORK	93.855	125,578
LC: HIV VACCINE TRIALS NETWORK	93.855	67,557
LC: HIV VACCINE TRIALS NETWORK	93.855	470,200
LC: HIV VACCINE TRIALS NETWORK	93.855	12,510
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	69,471
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	258,360
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	10,000
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	2,202
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	8,037
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	64,938



**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	\$ 34,776
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	108,850
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	2,173
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	93.855	47,058
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICROBICIDE TRIALS NETWORK	93.855	11,191
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICROBICIDE TRIALS NETWORK	93.855	6,706
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICROBICIDE TRIALS NETWORK	93.855	22,315
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICROBICIDE TRIALS NETWORK	93.855	84,358
LEUKOCYTE TELOMERE LENGTH AND CARDIOVASCULAR DISEASE IN JACKSON HEART STUDY	93.837	49,583
LOC: HIV VACCINE TRIALS NETWORK	93.855	244,698
LOC: HIV VACCINE TRIALS NETWORK	93.855	6,250
LOC: HIV VACCINE TRIALS NETWORK	93.855	1,903
LOC: HIV VACCINE TRIALS NETWORK	93.855	10,281
LOC: HIV VACCINE TRIALS NETWORK	93.855	23,699
LOC: HIV VACCINE TRIALS NETWORK	93.855	31,319
LOC: HIV VACCINE TRIALS NETWORK	93.855	50,308
LOC: HIV VACCINE TRIALS NETWORK	93.855	87,270
LOC: HIV VACCINE TRIALS NETWORK	93.855	17,451
LOC: HIV VACCINE TRIALS NETWORK	93.855	22,311
LOC: HIV VACCINE TRIALS NETWORK	93.855	15,919
LOC: HIV VACCINE TRIALS NETWORK	93.855	4,148
LOC: HIV VACCINE TRIALS NETWORK	93.855	3,745
LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	0.00	17,008
LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	0.00	3,248
LOOKING BEYOND CYP17A: EXPLOITING PRERECEPTOR REGULATION TO OPTIMIZE NEXT- GENERATION STEROID-SYNTHESIS INHIBITION IN CASTRATION-RESISTANT PROSTATE CANCER	12.420	3,866

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	\$ (259)
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	37,826
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	259
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	309,801
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	49,339
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	160,826
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	(38)
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	42,943
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	38
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	228,998
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	129,655
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	48,470
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	16,961
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	5,853
MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	93.866	39,378
MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	93.866	26,685
MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	93.866	21,208
MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	93.866	131,529
METABOLITE BIOMARKERS IN THE DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA	93.394	34,182
METHODS FOR EVALUATING VACCINE EFFICACY	93.855	10,177
METHODS FOR EVALUATING VACCINE EFFICACY	93.855	112,997
MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	93.395	(14,672)

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	93.395	\$ 22,380
MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	93.395	14,672
MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	93.395	14,672
MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	93.395	89,880
MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	93.395	14,247
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	65,269
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	23,866
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	57,358
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	65,269
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	84,263
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	51,795
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	3,626
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	27,078
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	10,601
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	8,850

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	\$ 155,729
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	21,232
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	28,961
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	185,862
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	3,645
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	15,112
MOLECULAR CORRELATES OF OUTCOMES IN CLINICAL TRIALS OF COLON CANCER	93.393	70,023
MOLECULAR CORRELATES OF OUTCOMES IN CLINICAL TRIALS OF COLON CANCER	93.393	39,869
MOLECULAR CORRELATES OF OUTCOMES IN CLINICAL TRIALS OF COLON CANCER	93.393	17,395
NON INVASIVE BIOMARKERS FOR DIAGNOSING CLINICALLY SIGNIFICANT PROSTATE CANCER	93.394	36,017
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	1,746
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	8,521
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	4,950
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	6,280
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	16,262
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	6,353
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	31,309

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
NOVEL COMPUTATIONAL TOOLS FOR STUDYING THE HUMAN MICROBIOME	93.301	\$ 32,163
NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGINAL BACTERIA	93.310	16,030
NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGINAL BACTERIA	93.310	32,035
NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGINAL BACTERIA	93.310	24,354
NOVEL PATHOGEN ASSOCIATED CANCERS (PQ12)	93.393	110,561
NOVEL PATHOGEN ASSOCIATED CANCERS (PQ12)	93.393	123,117
NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)	93.393	2,280
NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)	93.393	12,395
NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)	93.393	31,030
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	3,900
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	2,166
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	14,656
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	17,648
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	9,756
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	23,249
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	50,241
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	84,410

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	\$ 139,915
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	43,938
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	25,625
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	59,260
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	34,240
OUTCOMES BASED GUIDELINE DEVELOPMENT FOR PROSTATE CANCER SCREENING AND TREATMENT	93.393	5,300
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER	93.395	2,585
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER	93.395	5,785
P31K SIGNALING AND BIOLOGY OF THERAPEUTIC RESPONSE IN BRAIN AND PROSTATE TUMORS	93.396	73,563
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	2,764
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	26,788
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	13,983
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	88,398
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	5,373
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	7,830
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	15,782
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	86,549
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	58,629
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	243,289
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	5,745
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	26,755
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	46,386
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	1,728
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	6,546
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	31,348
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	16,213
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	93.397	160,652

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
PCPT AND SELECT COHORTS: CORE INFRASTRUCTURE SUPPORT FOR CANCER RESEARCH	93.394	\$ 114,795
PCPT AND SELECT COHORTS: CORE INFRASTRUCTURE SUPPORT FOR CANCER RESEARCH	93.394	7,107
PCPT AND SELECT COHORTS: CORE INFRASTRUCTURE SUPPORT FOR CANCER RESEARCH	93.394	73,896
PEDIATRIC GLIOBLASTOMA THERAPIES BASED ON PATIENT-DERIVED STEM CELL RESOURCES	12.420	15,770
PERIPHERAL BLOOD BIOPSY FOR MOLECULAR DIAGNOSIS OF PANCREATIC CANCER	93.394	65,674
PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYSTROPHY	93.846	19,156
PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYSTROPHY	93.846	39,306
PREDICTION OF TREATMENT-RELATED MORTALITY AND THERAPEUTIC RESISTANCE IN AML	93.393	3,478
PREGNANCY OUTCOMES IN WOMEN WITH DISABILITIES: EXPLORATORY RESEARCH	93.865	28,753
PREGNANCY OUTCOMES IN WOMEN WITH DISABILITIES: EXPLORATORY RESEARCH	93.865	7,171
PREP EXPOSURE DURING HIV-1 INFECTION AND THE RISK OF LOW-FREQUENCY ARV RESISTANCE	93.855	22,186
PREP EXPOSURE DURING HIV-1 INFECTION AND THE RISK OF LOW-FREQUENCY ARV RESISTANCE	93.855	1,409
PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS	93.395	6,430
PROFILING CANCER NEOANTIGEN REPERTOIRES AND VALIDATING IMMUNOTHERAPY TARGETS	93.394	63,683
PROGNOSTIC AND FUNCTIONAL SIGNIFICANCE OF ADHESION MOLECULES IN PEDIATRIC AML	93.394	14,196
PROMISS: PROSTATE MODELING TO IDENTIFY SURVEILLANCE STRATEGIES	93.393	10,607
PROMISS: PROSTATE MODELING TO IDENTIFY SURVEILLANCE STRATEGIES	93.393	6,513
PROMISS: PROSTATE MODELING TO IDENTIFY SURVEILLANCE STRATEGIES	93.393	23,106
PROMISS: PROSTATE MODELING TO IDENTIFY SURVEILLANCE STRATEGIES	93.393	42,615
PROMISS: PROSTATE MODELING TO IDENTIFY SURVEILLANCE STRATEGIES	93.393	12,539

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
PROSPECTIVE COMPARATIVE EFFECTIVENESS TRIAL FOR MALIGNANT BOWEL OBSTRUCTION	93.226	\$ 21,258
PROSPR: STATISTICAL COORDINATING CENTER (PSCC)	93.393	17,823
PROSPR: STATISTICAL COORDINATING CENTER (PSCC)	93.393	40,026
PROSPR: STATISTICAL COORDINATING CENTER (PSCC)	93.393	9,970
PROTEIN BIOMARKERS IN CHILDHOOD ACUTE MYELOID LEUKEMIA	93.394	5,526
RANDOMIZED TRIAL OF WEB-DELIVERED ACCEPTANCE THERAPY FOR SMOKING CESSATION	93.393	8,571
RANDOMIZED TRIAL OF WEB-DELIVERED ACCEPTANCE THERAPY FOR SMOKING CESSATION	93.393	5,192
ROLE OF THE PERIVASCULAR MICROENVIRONMENT IN PRIMARY AND METASTATIC BRAIN TUMORS	93.397	244,524
ROLE OF THE PERIVASCULAR MICROENVIRONMENT IN PRIMARY AND METASTATIC BRAIN TUMORS	93.397	58,321
ROLE OF THE PERIVASCULAR MICROENVIRONMENT IN PRIMARY AND METASTATIC BRAIN TUMORS	93.397	12,026
SDMC: HIV PREVENTION TRIALS NETWORK	93.855	73,530
SDMC: HIV PREVENTION TRIALS NETWORK	93.855	17,343
SDMC: MICROBICIDE TRIALS NETWORK	93.855	57,088
SDMC: MICROBICIDE TRIALS NETWORK	93.855	12,369
SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	93.397	35,569
SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	93.397	45,615
SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	93.397	58,537
SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	93.397	94,354
SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	93.397	58,432
SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	93.397	85,659
SEATTLE VACCINE TRIALS UNIT	93.855	205,285



**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
SEATTLE-LAUSANNE-KAMPALA CTU	93.855	\$ 122,934
SEATTLE-LAUSANNE-KAMPALA CTU	93.855	360,609
SEATTLE-LAUSANNE-KAMPALA CTU	93.855	118,848
SEATTLE-LAUSANNE-KAMPALA CTU	93.855	125,347
SEATTLE-LAUSANNE-KAMPALA CTU	93.855	35,376
SINGLE-CELL METHODS FOR ANALYSIS OF CLONAL HETEROGENEITY AND EVOLUTION IN CANCER	93.394	82,039
SINGLE-CELL METHODS FOR ANALYSIS OF CLONAL HETEROGENEITY AND EVOLUTION IN CANCER	93.394	105,623
SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER STATISTICAL METHODS FOR INTEGRATIVE ANALYSIS OF GENOMICS AND PROTEOMICS DATA	93.395	2,380,335
STATISTICAL METHODS FOR MEDICAL STUDIES	93.859	53,786
STATISTICAL METHODS FOR MEDICAL STUDIES	93.393	5,417
STATISTICAL METHODS FOR MEDICAL STUDIES	93.393	26,633
STATISTICAL METHODS FOR MEDICAL STUDIES	93.393	6,669
STATISTICAL METHODS FOR PROSPECTIVE EVALUATION OF BIOMARKERS	93.859	9,036
STATISTICAL METHODS FOR SELECTION AND EVALUATION OF BIOMARKERS	93.859	5,424
STATISTICAL METHODS FOR SELECTION AND EVALUATION OF BIOMARKERS	93.859	1,403
STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS	93.855	36,926
STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS	93.855	75,875
STEROID TRANSPORT PROTEINS IN CASTRATION-RESISTANT PROSTATE CANCER	12.420	13,181
STRATEGIES TO IMPROVE THE ADOPTIVE TRANSFER OF T CELLS	93.396	60,232
STRATEGIES TO IMPROVE THE ADOPTIVE TRANSFER OF T CELLS	93.396	8,969
SWOG STATISTICS AND DATA MANAGEMENT CENTER T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS	93.395	799,870
T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS	93.855	132
T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS	93.855	319,755
TARGETED INTERVENTION FOR BIPOLAR SMOKERS	93.279	22,688
TARGETED INTERVENTION FOR BIPOLAR SMOKERS	93.279	16,397
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	3,538

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	\$ 17,540
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	39,639
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	145,807
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	3,630
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	89,266
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	42,519
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	220,145
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	40,985
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	89,498
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	96,339
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	27,099
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	881,874
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	38,725
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	228,897
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	2,900
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	335,354
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	113,899
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	322,522
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	13,413
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	35,557

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

Subaward title	CFDA number	Amount
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	\$ 192,652
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	72,838
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	2,480
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	85,674
TARGETED RADIOTHERAPY WITH 90Y-BC8 MONOCLONAL ANTIBODY, FLUDARABINE AND TBI FOLLOWED BY HLA-MATCHED, ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR THE TREATMENT OF MULTIPLE MYELOMA	93.395	22,014
TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMORY T CELLS	93.395	8,098
TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMORY T CELLS	93.395	141,493
TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL	93.393	145,910
TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL	93.393	63,192
TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL	93.393	32,520
TELOMERES DYNAMICS, CARDIOVASCULAR RISK, AND LONGEVITY IN OLDER WOMEN	0.00	425,436
THE GENETICS OF PARALLEL REPRODUCTIVE ISOLATION IN STICKLEBACK SPECIES PAIRS	93.859	1,640
THE HIPPO PATHWAY IN PROSTATE GLAND HOMEOSTASIS AND PROSTATE CANCER	93.396	21,933
THE HIPPO PATHWAY IN PROSTATE GLAND HOMEOSTASIS AND PROSTATE CANCER	93.396	1,629
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	96,017
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	2,818
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	6,455

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	\$ 7,395
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	31,160
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	25,000
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	25,000
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	2,439
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	29,952
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	9,128
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	37,507
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	49,681
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	46,346
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	45,904
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	10,592
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	40,050
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	50,038

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.399	\$ 10,174
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	103,056
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	8,095
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	238,877
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	62,648
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	25,000
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	25,000
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	25,000
THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	93.853	35,783
THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	93.853	143,175
THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	93.853	207,696
THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	93.853	29,774
THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	93.853	134,524
THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSION	93.855	6,886
THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSION	93.855	39,941
THE ROLE OF COORDINATING CENTERS IN COLLABORATIVE CANCER-EPIDEMIOLOGY STUDIES	93.393	7,682
THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS	93.855	290,380

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS	93.855	\$ 173,827
THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOMETRY DATA	93.286	6,049
THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOMETRY DATA	93.286	59,002
THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOMETRY DATA	93.286	31,566
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	2,987
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	2,612
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	12,756
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	46,389
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	2,730
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	21,090
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	27,377
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	236,311
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	15,502
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	15,414
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	14,000
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	21,812
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	37,041
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	(15,414)
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	(14,000)
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	14,000

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<b>Subaward title</b>	<b>CFDA number</b>	<b>Amount</b>
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	\$ 15,414
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	41,449
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	105,547
TOWARDS A MODEL OF FANCONI ANEMIA	93.701	7,009
TRANSLATIONAL STUDIES OF INHERITED MARROW FAILURE AND MYELODYSPLASTIC SYNDROMES	93.847	160,595
TREC COORDINATION CENTER	93.394	2,319
TREC COORDINATION CENTER	93.394	29,902
TREC COORDINATION CENTER	93.394	26,624
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	5,228
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	41,995
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	24,424
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	33,133
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	69,094
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	21,997
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	8,686
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	107,647
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	145,031
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	463
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	27,660
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	23,636
USING MOUSE MODELS TO PROBE THE RELATIONSHIP OF ONCOGENESIS TO DEVELOPMENT AND ONCOGENIC MUTATIONS	93.396	97,699
VITAMIN D AND PROSTATE CANCER: BIOMARKERS AND GENETIC VARIATION	93.393	13,159

**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
WEIGHT LOSS AND CANCER BIOMARKERS IN WOMEN: OXIDATIVE STRESS AND INFLAMMATION	93.393	\$ 87,199
WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME	93.839	7,938
WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME	93.839	100,353
WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME	93.839	5,619
WOMEN'S HEALTH INITIATIVE CANCER SURVIVOR COHORT	93.393	190,776
WOMEN'S HEALTH INITIATIVE CANCER SURVIVOR COHORT	93.393	148,771
WOMEN'S HEALTH INITIATIVE CANCER SURVIVOR COHORT	93.393	17,842
		<u>\$ 59,881,406</u>



**FRED HUTCHINSON CANCER RESEARCH CENTER  
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2014

**(1) Summary of Auditors' Results**

***Financial Statements***

Type of auditors' report issued: **Unmodified**

Internal control over financial reporting:

- Material weakness(es) identified: **No**
- Significant deficiency(ies) identified that are not considered to be material weaknesses: **No**

Noncompliance material to financial statements noted: **No**

***Federal Awards***

Internal control over major programs:

- Material weakness(es) identified: **No**
- Significant deficiency(ies) identified that are not considered to be material weaknesses: **No**

Type of auditors' report issued on compliance for major programs: **Unmodified**

Any audit findings disclosed that are required to be reported in accordance with Section 510(a) of OMB Circular A-133: **No**

Identification of major program:

<b>Federal grantor and program title</b>	<b>CFDA number</b>
Research and Development Cluster	Various

Dollar threshold used to distinguish between type A and type B programs: **\$3,000,000**

Auditee qualified as low-risk auditee: **Yes**

**(2) Financial Statement Findings**

None.

**(3) Federal Award Findings and Questioned Costs**

No findings.